WO2004076622A2

WO2004076622A2 - Regulation of gene expression by dna interference

Info

Publication number: WO2004076622A2
Application number: PCT/JP2004/001433
Authority: WO
Inventors: Kazunari Taira; Hiroaki Kawasaki
Original assignee: National Institute Of Advanced Industrial Science And Technology
Priority date: 2003-02-10
Filing date: 2004-02-10
Publication date: 2004-09-10
Also published as: KR20050115231A; JP2006519008A; AU2004215097A1; CA2515586A1; EP1592791A2; WO2004076622A3; US20060247193A1; CN1768139A

Abstract

The present invention provides products and methods for modulating expression of a target gene in a cell. One such method includes introducing into the cell a polynucleotide that forms a duplex region with an mRNA transcribed from said target gene, where the duplex region comprises a mammalian miRNA target region. Another such method includes introducing into the cell an siRNA that forms a duplex region with an miRNA, or precursor thereof, where an mRNA transcribed from the target gene comprises a miRNA target region. In certain preferred embodiments, the methods further include measuring expression of the target gene. The methods are particularly useful for modulating ontogenesis, function, differentiation and/or viability of a mammalian cell. As such, the invention also provides methods for controlling ontogenesis of mammal, function of mammalian cell, differentiation of mammalian cell or viability of mammalian cell in the post-transcriptional phase by introducing into the cell a miRNA or a siRNA silencing precursor to the miRNA. The invention additionally provides polynucleotides, including vectors, useful in the method of the instant invention. The provided polynucleotides include a plasmid vector comprising a promoter and a polynucleotide sequence expressing miRNA or precursor to the miRNA. Also included is a plasmid vector comprising a promoter and a nucleotide sequence expressing siRNA silencing precursor to miRNA. In certainpreferred embodiments, the miRNA is capable of forming a duplex region with an mRNA transcribed from a mammalian target gene.

Description

DESCRIPTION REGULATION OF MAMMALIAN CELLS

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/445,829, filed February. 10, 2003, the entirety of which is herein incorporated by reference.

FIELD OF THE INVENTION The invention relates to processes for modulating gene expression in mammalian cells as well as to products and compositions useful in such methods. The methods and compositions are useful, by way of example, for controlling ontogenesis, function, differentiation and/or viability of a mammalian cell.

BACKGROUND OF THE INVENTION Noncoding RNAs including rRNA, snRNA, snoRNA and tRNA have roles in a great variety of processes such as chromosome maintenance, gene imprinting, transcriptional regulation, pre-mRNA splicing and the control of mRNA translation¹. One class of the noncoding RNAs called microRNAs (miRNAs) is small RNAs that are known to regulate mRNA at a post-transcriptional level^2"18. To date, a large number of miRNAs has been discovered in animals and plants²-³ _' ⁶'¹⁶. Among them, lin -4 and let-Ya e identified from the genetic analysis of developmental timing in

Caenorhabditis elegans, and are well characterized^2'5. Both lin-4 and let-7 act as repressors of their respective target genes, such as lin-14, lin-28, and Hn41. Repression by these miRNAs requires the presence of partially complementary sequences in the 3' -untranslated regions (3'-UTRs) of the target mRNAs. Although lin-14 and lin-28axe translationally repressed by lin-4, these mRNAs were detected in association with polyribosomes¹⁹>²⁰. Thus, lin-4 regulates expression of the target genes after translational initiation.

In general, miRNAs are first transcribed as a long RNA and then processed to a pre-miRNA of approximately ~70 nts²¹. This pre-miRNA is transported to the cytoplasm and processed by RNase III Dicer to produce the mature miRNA²¹"²⁴. The mature miRNA is incorporated into ribonucleoprotein complexes (miRNPs) including eIF2C2, which functions in RNA interference (RNAi) -mediated gene silencing⁹- ¹⁶-²⁵. This miRNA-miRNPs complex represses mRNA translation by partially base-pairing to the 3'-UTR of target mRNAs²'^-²⁷. However, Arabidopsis thaliana miR-171 and iR- 165/166 are perfectly complementary to the coding region of the Scarβerow-like (SCI) family of the putative transcription factor, PHAVOLUTA (PUΫ) and PHABULOSA (PHB) mRNA, respectively¹⁷-¹⁸. These miRNAs can induce cleavage of the mRNAs similar to siRNA-mediated mRNA degradation. Thus, miRNAs have functions including repression of the mRNA translation and cleavage of mRNAs.

In general, miRNAs including lin-4 and let-7 control the mRNA translation by

partially base-pairing to the 3'-UTR region of target mRNA^2"5. In Arabidopsis

thaliana, miR-171 and miR-165/166 are perfectly complementary to coding region of

Scarecrow-like (SCL) family mRNA, PHAVOLUTA (PHV) and PHABULOSA (PHB)

mRNA, respectively¹⁷'¹⁸. These miRNAs cleave their target mRNAs, resulting in

siRNA-like gene silencing. It has been proposed that there is only a single pathway

shared by both miRNAs and siRNAs and that this single pathway mediates both translational control and mRNA cleavage⁴³.

In C. elegans, let-7and lin-4 axe expressed sequentially during development^2"5-¹⁹. Thus, since miRNAs suppress the expression of the lin-41 and lin-14/28 enes that are necessary for normal development of C. elegans, it is likely that these miRNAs play important roles in development^{2 5}. In plants, several genes that are targets of miRNAs, including genes in the SCL family, have been identified and their functions have been characterized¹⁷-¹⁸. SCL family, a target of miR-171, controls a wide range of developmental processes, including radial patterning in roots and hormone signaling. In addition, miR- 165/166 can regulate the expression of PHV and PHB genes that encode homeodomain-leucine zipper transcription factors implicated in the perception of radial position in the shoot tissues that give rise to leaves. Moreover, bantam mieroRNA simultaneously stimulates cell proUferation and prevents apoptosis during Drosophila development⁴⁴. Thus, a number of miRNAs have been identified as playing important roles in the development of animals and plants.

Although more than two hundred miRNAs have been found in mammals, the target mRNAs of these known miRNAs remain to be identified. In view of the well established need in the art for additional means to regulate gene expression in mammalian systems, identifying the miRNA target sequences for those known mammalian miRNAs would have great implications for controlling ontogenesis, function, differentiation and/or viability of a mammalian cell. SUMMARY OF THE INVENTION

The present invention provides products and methods for modulating expression of a target gene in a cell. One such method comprises introducing into the cell a polynucleotide that forms a duplex region with an mRNA transcribed from said target gene, wherein the duplex region comprises a mammalian miRNA target region. Another such method comprises introducing into the cell an siRNA that forms a duplex region with an miRNA, or precursor thereof, wherein an mRNA transcribed from the target gene comprises a miRNA target region. In certain preferred embodiments, the methods further comprise measuring expression of the target gene. The methods are particularly useful for modulating ontogenesis, function, differentiation and/or viability of a mammalian cell. As such, the invention also provides methods for controlling ontogenesis of mammal, function of mammalian cell, differentiation of mammalian cell or viability of mammalian cell in the post-transcriptional phase by introducing into the cell a miRNA or a siRNA silencing precursor to the miRNA. The invention additionally provides polynucleotides, including miRNAs, siRNAs, and vectors, useful in the method of the instant invention. The provided vectors include a plasmid vector comprising a promoter and a polynucleotide sequence expressing miRNA or a precursor to the miRNA. Also included is a plasmid vector comprising a promoter and a nucleotide sequence expressing siRNA silencing precursor to miRNA. In certain preferred embodiments, the miRNA is capable of forming a duplex region with an mRNA transcribed from a mammalian target gene. BRIEF DESCRIPTION OF THE DRAWINGS Figures la^_le. Hesl (NM_005524) is a target of miR-23. a, The prediction of secondary structures between miR-23 and its target RNAs. A region sharing high homology to human and mouse miR-23 is located in the coding region, near the termination codon (box), of human Hairy HES1 (NM_005524), mouse Hesl, and human Homolog HES1 (Y07572) mRNAs (top), b, Human Hairy HES1 (NM_005524) mRNA has three target regions (motifs I, II and III) of miR-23 (bottom). Motif III has a K box sequence (black box) that is known, at least in the case of Drosophila, to be involved in post-transcriptional negative regulation, c, The level of Hesl in NT2 cells in the presence or absence of RA (5 μM, for 3 weeks). Values are means with S.D. of results from three replicates in each case, d, The relative level of Hesl mRNA in NT2 cells in the presence or absence of RA (5 μM, for 3 weeks). The relative level of Hesl mRNA was determined by Northern blotting analysis. N," nuclear fraction, Cl eytoplasmic fraction, e, The level of miR-23 in NT2 cells in the presence or absence of RA (5 μM, for 3 weeks) was determined by Northern blotting analysis.

Figures 2a^_2h. Effects of synthetic miR-23 and siRNA-miR-23 targeted to a loop region of the precursor to miR-23 on expression of the gene for Hesl. a, Sequences of synthetic miR-23, double stranded miR-23 and mutant miR-23. Asterisks indicate nucleotides mutated relative to those in the sequence of miR-23. b, The level of HES1 in undifferentiated NT2 cells that had been treated with synthetic miR-23 (100 nM) or with synthetic mutant miR-23 (100 nM) in the absence of RA. Values are means with S.D. of results from three replicates in each case, c, The level of HES1 in undifferentiated NT2 cells that had been treated with synthetic single stranded miR-23 (100 nM) or with synthetic double stranded miR-23 (100 nM) in the absence of RA. d, The level of Hesl mRNA in undifferentiated NT2 cells that had been treated with synthetic miR-23 or synthetic mutant miR-23 in the absence of RA. Nl nuclear fraction, C' eytoplasmic fraction, e, Sequences of synthetic siRNA-miR-23 and synthetic mutant siRNA-miR-23. f, The level of precursor and mature miR-23, as detected by Northern blotting analysis in NT2 cells in the presence of RA (5 μM, for 3 weeks). Actin mRNA was used as an endogenous control, g, The level of HES1 in NT2 cells in the presence of RA (5 μM). Values are means with S.D. of results from three replicates in each case, h, The level of Hesl mRNA in differentiated NT2 cells in the presence of RA (5 μM). NJ nuclear fraction, C>' eytoplasmic fraction.

Figures 3a- 3h. Target specificity of miR-23, as determined with plasmids that encoding a gene for luciferase fused to the sequences of three target motifs of miR-23 in Hairy HESl mRNA and Homolog HES1 mRNA. a, Sequences of genes for Luc-TM23, Luc-mutant TM23 and Luc-mutant motif. The target site of miR-23 or mutant miR-23 is in a black box. Asterisks indicate nucleotides mutated relative to those in the target site of miR-23. b, The activity of luciferase, due to the reporter genes, in NT2 cells in the presence or absence of RA (5 μM). Values are means with S.D. of results from three replicates in each case, c, The activity of luciferase, due to the reporter genes, in undifferentiated NT2 cells in the presence or absence of synthetic miR-23 or mutant miR-23. d, The activitiy of luciferase, due to the reporter genes, in differentiated NT2 cells in the presence or absence of siRNA-miR-23. e, Sequences of genes for Luc-TS23 and mutant Luc-TS23 (Luc-mTS23). The target site of miR-23 or mutant miR-23 is in a blue box. Asterisks indicate nucleotides mutated relative to those in the target site of miR-23. f, The activitiy of luciferase, due to the reporter genes, in NT2 cells in the presence or absence of RA (5 μM). Values are means with S.D. of results from three replicates in each case, g, The activitiy of luciferase, due to the reporter genes, in undifferentiated NT2 cells in the presence or absence of synthetic miR-23 or mutant miR-23. h, The activitiy of luciferase, due to the reporter genes, in differentiated NT2 cells in the presence or absence of siRNA-miR-23.

Figures 4a-4c. The role of miR-23 during the RA-induced neuronal differentiation of NT2 cells a, Effects of siRNA-miR-23 on RA-induced neuronal differentiation. Left panel, wild-type NT2 cells after treatment with RA (5 μM, for 3 weeks); middle panel, NT2 cells after treatment with siRNA-miR-23 and RA; right panel, NT2 cells after treatment with siRNA-miR-23, synthetic miR-23 and RA. Nuclei of each NT2 cell were stained with 4-diamidino-2-phenylindole (DAPI). b, The level of MAP2 after RA-induced (5 μM RA) neuronal differentiation, c, The level of SSEA-3 after RA-induced (5 μM RA) neuronal differentiation.

Figures 5. The effect of various miRNAs on expressions these target mRNAs. The levels of target proteins were analyzed by western blotting and calculated using NIH image program.

Table 1. Identification of target genes for various miRNAs. DETAILED DESCRIPTION

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

As used herein, the term "siRNA" refers to a double stranded RNA molecule which binds to a target polyribonucleotide. In a preferred embodiment, binding of the siRNA to the target molecule inhibits the function of the target polyribonucleotide. As used herein, the term "organism" refers to any living entity comprised of at least one cell. A living organism can be as simple as, for example, a single eukaryotic cell or complex multi-cellular animal, such as a mammal.

As used herein, the term "mammal" refers to members of the class Mammalia, including the primates. Particularly preferred members of the class Mammalia include human, cattle, goat, pig, sheep, rodent, hamster, mouse and rat.

The term "heterologous" refers to a combination of elements not naturally occurring. For example, heterologous DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell. A heterologous expression regulatory element is such an element operatively associated with a different gene than the one it is operatively associated with in nature.

As used herein, two polynucleotide sequences are said to be "substantially homologous" or to share "substantial homology" when they share about 70% identity. In a more preferred embodiment, polynucleotides sharing "substantial homology" are those having at least about 80% identity, more preferably at least about 90% identity, and still more preferably, at least about 95% identity. It is additionally preferred that such substantially homologous polynucleotides share a functional similarity. For example, in one particullary preferred embodiment, substantially homologous polynucleotides will hybridize under moderately or highly stringent hybridization conditions. In another preferred embodiment, substantially homologous polynucleotides function to encode polypeptides that share a biologically significant activity characteristic of the polypeptide.

Stringency of hybridization refers to conditions under which polynucleotide duplex is stable. As known to those of skill in the art, the stability of duplex is a function of salt concentration and temperature (See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 2d Ed. (Cold Spring Harbor Laboratory, (1989); incorporated herein by reference). Stringency levels used to hybridize a given probe with target-DNA can be readily varied by those of skill in the art. The phrase "low stringency hybridization" refers to conditions equivalent to hybridization in 10% formamide, 5x. Denhart's solution, 6x SSPE, 0.2% SDS at 42 degree C, followed by washing in lx SSPE, 0.2% SDS, at 50 degrees C. Denhart's solution and SSPE are well known to those of skill in the art as are other suitable hybridization buffers. (See, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989)

As used herein, the term "moderately stringent hybridization" refers to conditions that permit target-DNA to bind a complementary nucleic acid that has about 70% identity, preferably about 75% identity, more preferably about 85% identity to the target DNA; with greater than about 90% identity to target-DNA being especially preferred. Preferably, moderately stringent conditions are conditions equivalent to hybridization in 50% formamide, 5x Denhart's solution, 5x SSPE, 0.2% SDS at 42 degrees C, followed by washing in 0.2x SSPE, 0.2% SDS, at 65 degrees C. Additional examples of typical "moderately stringent conditions" include 0.015 M sodium chloride, 0.0015 M sodium citrate at 50-65 degrees C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 20% formamide at 37-50 degrees C. For the purposes of illustration, a "moderately stringent" condition of 50 degrees C in 0.015 M sodium ion is expected to allow about a 20% mismatch.

The term "highly stringent hybridization" refers to conditions that permit hybridization of only those nucleic acid sequences that that share a high degree identity. High stringency conditions can be provided, for example, by hybridization in 50% formamide, 5x Denhart's solution, 5x SSPE, 0.2% SDS at 42.degrees C, followed by washing in O.lx SSPE, and 0.1% SDS at 65 degrees C. Additional examples of "highly stringent conditions" for hybridization and washing include 0.015M sodium chloride, 0.0015M sodium citrate at 65-68 degrees C or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide at 42.degrees.

The "percent identity" between the two sequences is a function of the number of identical positions shared by the sequences. The determination of percent identity between two sequences can be accomplished using any conventional mathematical algorithm, such as the BLAST algorithm by Karlin and Altschul (S. Karlin and S.F. Altschul, Proc. Natl. Acad. Sci. USA. 1990, 87: 2264-2268; S. Karlin and S.F. Altschul, Proc. Natl. Acad. Sci. USA. 1993, 90: 5873-5877). The BLAST algorithm is incorporated into the BLASTN program of Altschul et al. (S.F. Altschul et al., J. Mol. Biol. 1990, 215: 403). When a nucleotide sequence is analyzed according to BLASTN, suitable parameters include, for example, a score= 100 and word length= 12. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389. When utilizing BLAST and Gapped BLAST, the default parameters of the respective programs are preferably used. However, one skilled in the art can readily adjust the parameters to suit a particular purpose. Specific procedures for such analysis are known in the art (See, for example, the BLAST website of the National Center for Biotechnology Information.)

The term "corresponding to" is used herein to refer to similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured. A nucleic acid or amino acid sequence alignment may include spaces. Thus, the term "corresponding to" refers to the sequence similarity, and not the numbering of the amino acid residues or nucleotide bases. A "vector" is a recombinant nucleic acid construct, such as plasmid, phage genome, virus genome, cosmid, or artificial chromosome to which another DNA segment may be attached. In a specific embodiment, the vector may bring about the replication of the attached segment, e.g., in the case of a cloning vector. A "rephcon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo, i.e., it is capable of replication under its own control. Other preferred examples of vectors include expression vectors comprising expression control sequences.

"Expression control sequences", e.g., transcriptional and translational control sequences, are regulatory sequences that flank a coding sequence, such as promoters, enhancers, suppressors, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences. On mRNA, a ribosome binding site is one example of an expression control sequence. The term "gene" as used herein refers to a portion of a DNA molecule that includes a polypeptide coding sequence operatively associated with one or more expression control sequences. In one embodiment, a gene can be a genomic or partial genomic sequence, in that it contains one or more introns. In another embodiment, a gene can be a cDNA molecule (i.e., the coding sequence lacking any introns). The gene herein after referred to as "dbl proto-oncogene" (or alternatively as dbl) is well-known in the art. (For a non-limiting example, see GenBank Accession X12556, herein incorporated by reference.) As used herein, the term "dbl proto-oncogene" (as well as dbl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the dbl proto-oncogene set forth in SEQ ID No:291. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 121.

The gene herein after referred to as "transforming growth factor beta 1" (or alternatively as TGFBI) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_000660, herein incorporated by reference.) As used herein, the term "transforming growth factor beta" (as well as TGFBI) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the gene for the transforming growth factor beta set forth in SEQ ID No:292. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 122.

The gene herein after referred to as "transforming growth factor alpha" (or alternatively as TGFA or TGF alpha) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_003236, herein incorporated by reference.) As used herein, the term "transforming growth factor alpha" (as well as TGFA or TGF alpha) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the transforming growth factor alpha set forth in SEQ ID No:293. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 123.

The gene herein after referred to as "v-myb myeloblastosis viral oncogene homolog" (or alternatively as V-myb or MYB) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_005375, herein incorporated by reference.) As used herein, the term "v-myb myeloblastosis viral oncogene homolog" (as well as V-myb or MYB) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the vmyb myeloblastosis viral oncogene homolog set forth in SEQ ID No:294. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in one or more of SEQ ID Nos: 124 and 185.

The gene herein after referred to as "c-cbl proto-oncogene" (or alternatively as c-cbl) is well-known in the art. (For a non-limiting example, see GenBank Accession X57110, herein incorporated by reference.) As used herein, the term "c-cbl proto-oncogene" (as well as c-cbl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the c-cbl proto-oncogene set forth in SEQ ID No:295. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 125.

The gene herein after referred to as "snol" (or alternatively as SNO I) is well-known in the art. (For a non-hmiting example, see GenBank Accession Z19588, herein incorporated by reference.) As used herein, the term "snol" (as well as SNO I) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the snol set forth in SEQ ID No:296. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 126.

The gene herein after referred to as "activin beta E subunit" (or alternatively as Activin beta) is well-known in the art. (For a non-limiting example, see GenBank Accession AF412024, herein incorporated by reference.) As used herein, the term "activin beta E subunit" (as well as Activin beta) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the activin beta E subunit set forth in SEQ ID No:297. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 127.

The gene herein after referred to as "myogenic factor 5" (or alternatively as Myf-5 or MYF5) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_005593, herein incorporated by reference.) As used herein, the term "myogenic factor 5" (as well as Myf-5 or MYF5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the myogenic factor 5 set forth in SEQ ID No:298. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in one or more of SEQ ID Nos:" 128 and 267.

The gene herein after referred to as "fibroblast growth factor 9" (or alternatively as FGF9 or glia-activating factor) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_002010, herein incorporated by reference.) As used herein, the term "fibroblast growth factor 9" (as well as FGF9 and glia-activating factor) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the fibroblast growth factor 9 set forth in SEQ ID No:299. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 129.

The gene herein after referred to as "RON encoding a tyrosine kinase" (or alternatively as RON) is well-known in the art. (For a non-hmiting example, see GenBank Accession X70040, herein incorporated by reference.) As used herein, the term "RON encoding a tyrosine kinase" (as well as RON) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the RON encoding a tyrosine kinase set forth in SEQ ID No:300. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 130.

The gene herein after referred to as "E3 ubiquitin ligase SMURFl" (or alternatively as SMURFl) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_020429, herein incorporated by reference.) As used herein, the term "E3 ubiquitin hgase SMURFl" (as weU as SMURFl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the E3 ubiquitin ligase SMURFl set forth in SEQ ID No:301. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 131.

The gene herein after referred to as "jagged 2" (or alternatively as JAG2) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_002226, herein incorporated by reference.) As used herein, the term "jagged 2" (as well as JAG2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the jagged 2 set forth in SEQ ID No:302. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No= 132.

The gene herein after referred to as "jun-B encoding the JUN-B protein" (or alternatively as JunB) is well-known in the art. (For a non-hmiting example, see GenBank Accession X51345, herein incorporated by reference.) As used herein, the term "jun-B encoding the JUN-B protein" (as well as JunB) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the jun-B encoding the JUN-B protein set forth in SEQ ID No:303. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 133.

The gene herein after referred to as "methyl-CpG binding domain protein 4" (or alternatively as MBD4) is well-known in the art. (For a non-limiting example, see GenBank Accession NM 303925, herein incorporated by reference.) As used herein, the term "methyl-CpG binding domain protein 4" (as well as MBD4) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the methyl-CpG binding domain protein 4 set forth in SEQ ID No-'304. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 134.

The gene herein after referred to as "ZIP kinase" (or alternatively as ZIP Kinase) is well-known in the art. (For a non-limiting example, see GenBank Accession AB022341, herein incorporated by reference.) As used herein, the term

"ZIP kinase" (as well as ZIP Kinase) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the ZIP kinase set forth in SEQ ID No:305. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 135.

The gene herein after referred to as "endomucin" (or alternatively as Endomucin or EMCN) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_016242, herein incorporated by reference.) As used herein, the term "endomucin" (as well as Endomucin or EMCN) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the endomucin set forth in SEQ ID No:306. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 136.

The gene herein after referred to as "ICE -protease activating factor" (or alternatively as IPAF) is well-known in the art. (For a non-hmiting example, see GenBank Accession AY035391, herein incorporated by reference.) As used herein, the term "ICE -protease activating factor" (as well as IPAF) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the ICE -protease activating factor set forth in SEQ ID No:307. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 137. The gene herein after referred to as "hairy and enhancer of split 1" (or alternatively as HESl) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM D05524, herein incorporated by reference.) As used herein, the term "hairy and enhancer of split 1" (as well as Hesl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the hairy and enhancer of split 1 set forth in SEQ ID No:308. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in one or more of SEQ ID Nos: 5 , 6, 7 and 171. The gene herein after referred to as "transforming growth factor beta 3 " (or alternatively as TGF-B3 or TGFB3, ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_003239, herein incorporated by reference.) As used herein, the term "transforming growth factor beta 3 " (as well as TGF-B3 or TGFB3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the transforming growth factor beta 3 set forth in SEQ ID No:309. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 138.

The gene herein after referred to as "enaptin mRNA" (or alternatively as enaptin) is well-known in the art. (For a non-limiting example, see GenBank

Accession AF535142, herein incorporated by reference.) As used herein, the term "enaptin mRNA" (as well as enaptin) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the enaptin mRNA set forth in SEQ ID No:310. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 139.

The gene herein after referred to as "AMP deaminase" (or alternatively as AMPD3) is well-known in the art. (For a non-limiting example, see GenBank Accession M84721, herein incorporated by reference.) As used herein, the term "AMP deaminase" (as well as AMPD3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the AMP deaminase set forth in SEQ ID No:311. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 140.

The gene herein after referred to as "interleukin 1 alpha" (or alternatively as ILIA, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession AF536338, herein incorporated by reference.) As used herein, the term "interleukin 1 alpha" (as well as ILIA) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the interleukin 1 alpha set forth in SEQ ID No:312. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 141.

The gene herein after referred to as "E2F transcription factor 6" (or alternatively as E2F6) is well-known in the art. (For a non-hmiting example, see

GenBank Accession NM_001952, herein incorporated by reference.) As used herein, the term "E2F transcription factor 6" (as well as E2F6) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the E2F transcription factor 6 set forth in SEQ ID No:313. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 142.

The gene herein after referred to as "laminin alpha" (or alternatively as laminin alpha or LAMA) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_005559, herein incorporated by reference.) As used herein, the term "laminin alpha" (as well as laminin alpha or LAMA) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the laminin alpha set forth in SEQ ID No: 314. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 143.

The gene herein after referred to as "polymerase (DNA-directed) alpha" (or alternatively as DNA Pol alpha or POLA2) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_002689, herein incorporated by reference.) As used herein, the term "polymerase (DNA-directed) alpha" (as well as DNA Pol alpha or POLA2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the polymerase (DNA-directed) alpha set forth in SEQ ID No:315. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 144.

The gene herein after referred to as "leukocyte tyrosine kinase" (or alternatively as LTK) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_002344, herein incorporated by reference.) As used herein, the term "leukocyte tyrosine kinase" (as well as LTK) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the leukocyte tyrosine kinase set forth in SEQ ID No:316. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 145.

The gene herein after referred to as "homeo box DI" (or alternatively as HOXD 1, ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_024501, herein incorporated by reference.) As used herein, the term "homeo box DI" (as well as HOXDl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the homeo box DI set forth in SEQ ID No:317. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 146. The gene herein after referred to as "laminin gamma " (or alternatively as

LAMB2 or laminin gamma) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM 302293, herein incorporated by reference.) As used herein, the term "laminin gamma" (as well as LAMB2 or laminin gamma) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the laminin gamma (formerly LAMB2) set forth in SEQ ID No:318. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 147.

The gene herein after referred to as "tumor necrosis factor receptor superfamily member 1A" (or alternatively as TNFRl) is well-known in the art. (For a non-limiting example, see GenBank Accession BC010140, herein incorporated by reference.) As used herein, the term "tumor necrosis factor receptor superfamily member 1A" (as well as TNFRl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the tumor necrosis factor receptor superfamily member 1A set forth in SEQ ID No:319. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in one or more of SEQ ID Nos:" 148 and 200. The gene herein after referred to as "villin 2" (or alternatively as Villin2 or

VTL2) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_003379, herein incorporated by reference.) As used herein, the term "villin 2" (as well as Villin2 or VIL2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the villin 2 set forth in SEQ ID No:320. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 149.

The gene herein after referred to as "frizzled homolog 5" (or alternatively as Frizzled homolog 5 or FZD5, ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_003468, herein incorporated by reference.) As used herein, the term "frizzled homolog 5" (as well as Frizzled homolog 5 or FZD5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the frizzled homolog 5 set forth in SEQ ID No:321. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 150.

The gene herein after referred to as "ATP-dependent chromatin remodelling protein" (or alternatively as ACFl) is well-known in the art. (For a non-limiting example, see GenBank Accession AF213467, herein incorporated by reference.) As used herein, the term "ATP-dependent chromatin remodelling protein" (as well as ACFl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the ATP-dependent chromatin remodelling protein set forth in SEQ ID No:322. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 151.

The gene herein after referred to as "MSX2 mRNA for transcription factor" (or alternatively as MSX2, ) is well-known in the art. (For a non-limiting example, see GenBank Accession X69295, herein incorporated by reference.) As used herein, the term "MSX2 mRNA for transcription factor" (as well as MSX2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the MSX2 mRNA for transcription factor set forth in SEQ ID No:323. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 152.

The gene herein after referred to as "adipose differentiation-related protein" (or alternatively as ADFP) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_001122 , herein incorporated by reference.) As used herein, the term "adipose differentiation-related protein" (as well as ADFP) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the adipose differentiation-related protein set forth in SEQ ID No:324. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 153. The gene herein after referred to as "myogenic factor 4" (or alternatively as myogenin or Myf-4 or MYOG) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_002479, herein incorporated by reference.) As used herein, the term "myogenic factor 4" (as well as myogenin or Myf-4 or MYOG) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the myogenin (myogenic factor 4) set forth in SEQ ID No:325. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 154. The gene herein after referred to as "SRY (Sex determining Region Y)-box 5"

(or alternatively as Sox- 5 or SOX5, ) is well-known in the art. (For a non-limiting example, see GenBank Accession NMJ306940, herein incorporated by reference.) As used herein, the term "SRY (Sex determining Region Y)-box 5" (as well as Soχ-5 or SOX5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the SRY (Sex determining Region Y)-box 5 set forth in SEQ ID No:326. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 155.

The gene herein after referred to as "Notch homolog 1" (or alternatively as Notchl, ) is well-known in the art. (For a non-limiting example, see GenBank

Accession NM_017617, herein incorporated by reference.) As used herein, the term "Notch homolog 1" (as well as Notchl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the Notch homolog 1 set forth in SEQ ID No:327. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 156.

The gene herein after referred to as "Human tyrosine kinase-type receptor" (or alternatively as ErbB2 or HER2) is well-known in the art. (For a non-limiting example, see GenBank Accession M11730, herein incorporated by reference.) As used herein, the term "Human tyrosine kinase-type receptor" (as well as ErbB2 or HER2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the Human tyrosine kinase-type receptor set forth in SEQ ID No:328. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 157.

The gene herein after referred to as "polymerase (DNA directed) theta" (or alternatively as DNA Pol theta or POLQ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_006596, herein incorporated by reference.) As used herein, the term "polymerase (DNA directed) theta" (as well as DNA Pol theta or POLQ) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the polymerase (DNA directed) theta set forth in SEQ ID No:329. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 158. The gene herein after referred to as "cAMP responsive element binding protein 3" (or alternatively as CREB3, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_006368, herein incorporated by reference.) As used herein, the term "cAMP responsive element binding protein 3" (as well as CREB3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the cAMP responsive element binding protein 3 set forth in SEQ ID No:330. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in one or more of SEQ ID Nos:"159 and 163.

The gene herein after referred to as "timeless homolog " (or alternatively as Timeless, ) is well-known in the art. (For a non-limiting example, see GenBank Accession BC050557, herein incorporated by reference.) As used herein, the term "timeless homolog " (as well as Timeless) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the timeless homolog set forth in SEQ ID No:331. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 160. The gene herein after referred to as "RAD52 homolog" (or alternatively as

RAD52, ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_002879, herein incorporated by reference.) As used herein, the term "RAD52 homolog" (as well as RAD52) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the RAD52 homolog set forth in SEQ ID No:332. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 161.

The gene herein after referred to as "toll-like receptor 4" (or alternatively as TLR4, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_138554, herein incorporated by reference.) As used herein, the term "toll- like receptor 4" (as well as TLR4) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the toll-like receptor 4 set forth in SEQ ID No-"333. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No^: 162. The gene herein after referred to as "SRY (Sex determining Region Y) -box 9" (or alternatively as SOX9, ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM__000346, herein incorporated by reference.) As used herein, the term "SRY (Sex determining Region Y)-box 9" (as well as SOX9) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the SRY (Sex determining Region Y)-box 9 set forth in SEQ ID No:334. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 164.

The gene herein after referred to as "homeo box A5" (or alternatively as HOXA5) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_019102, herein incorporated by reference.) As used herein, the term "homeo box A5" (as well as HOXA5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the homeo box A5 set forth in SEQ ID No:335. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 165.

The gene herein after referred to as "cell division cycle 42 GTP binding protein" (or alternatively as CDC42) is well-known in the art. (For a non-limiting example, see GenBank Accession BCO 18266, herein incorporated by reference.) As used herein, the term "cell division cycle 42 GTP binding protein" (as well as CDC42) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the cell division cycle 42 GTP binding protein set forth in SEQ ID No:336. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 166.

The gene herein after referred to as "desmuslin" (or alternatively as DMN) is well-known in the art. (For a non-hmiting example, see GenBank Accession

NM_145728, herein incorporated by reference.) As used herein, the term "desmuslin" (as well as DMN) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the desmuslin set forth in SEQ ID No:337. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 167.

The gene herein after referred to as "TFIIIC Box B-binding subunit" (or alternatively as TFIIIC Box B-binding subunit) is well-known in the art. (For a non-limiting example, see GenBank Accession U02619 , herein incorporated by reference.) As used herein, the term "TFIIIC Box B-binding subunit" (as well as TFIIIC Box B-binding subunit) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the TFIIIC Box B-binding subunit set forth in SEQ ID No=338. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in one or more of SEQ ID Nos:" 168 and 169.

The gene herein after referred to as "profilin 2" (or alternatively as PFN2) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_053024, herein incorporated by reference.) As used herein, the term "profilin 2" (as well as PFN2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the profilin 2 set forth in SEQ ID No:339. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 169.

The gene herein after referred to as "c-fms proto-oncogene" (or alternatively as c-fms) is well-known in the art. (For a non-hmiting example, see GenBank Accession X03663, herein incorporated by reference.) As used herein, the term "c-fms proto-oncogene" (as well as c-fms) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the c-fms proto-oncogene set forth in SEQ ID No:340. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 170.

The gene herein after referred to as "delta-like 1" (or alternatively as Delta lor DLL1, ) is well-known in the art. (For a non-limiting example, see GenBank

Accession NM 305618, herein incorporated by reference.) As used herein, the term "delta-like 1" (as well as Deltalor DLLl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the delta-like 1 set forth in SEQ ID No:341. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 172.

The gene herein after referred to as "fatty-acid-Coenzyme A hgase long-chain 5" (or alternatively as FACL5) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_016234, herein incorporated by reference.) As used herein, the term "fatty-acid-Coenzyme A ligase long-chain 5" (as well as FACL5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the fatty-acid-Coenzyme A ligase long-chain 5 set forth in SEQ ID No:342. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 173.

The gene herein after referred to as "discs large homolog-associated protein 2" (or alternatively as DLGAP2, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_004745, herein incorporated by reference.) As used herein, the term "discs large homolog-associated protein 2" (as well as DLGAP2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the discs large homolog-associated protein 2 set forth in SEQ ID No:343. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 174.

The gene herein after referred to as "TFIIH gene for transcription factor II H" (or alternatively as TFIIH, ) is well-known in the art. (For a non-limiting example, see GenBank Accession AB088103, herein incorporated by reference.) As used herein, the term "TFIIH gene for transcription factor II H" (as well as TFIIH) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the TFIIH gene for transcription factor II H set forth in SEQ ID No:344. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 176.

The gene herein after referred to as "RNA polymerase III subunit RPC" (or alternatively as RPC2, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_018082, herein incorporated by reference.) As used herein, the term "RNA polymerase III subunit RPC" (as well as RPC2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the RNA polymerase III subunit RPC set forth in SEQ ID No:345. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 177. The gene herein after referred to as "RecQ protein-like 5" (or alternatively as

RecQδ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_004259, herein incorporated by reference.) As used herein, the term "RecQ protein-like 5" (as well as RecQδ) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the RecQ protein-like 5 set forth in SEQ ID No:346. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 178.

The gene herein after referred to as "METH2 protein" (or alternatively as METH2, ) is well-known in the art. (For a non-limiting example, see GenBank Accession AF060153, herein incorporated by reference.) As used herein, the term "METH2 protein" (as well as METH2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the METH2 protein set forth in SEQ ID No^:347. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 179.

The gene herein after referred to as "MOST2 protein" (or alternatively as MOST2) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_020250, herein incorporated by reference.) As used herein, the term "MOST2 protein" (as well as MOST2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the MOST2 protein set forth in SEQ ID No:348. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 180. The gene herein after referred to as "SRY (Sex determining Region Y)-box 7"

(or alternatively as SOX7, ) is well-known in the art. (For a non-limiting example, see GenBank Accession NMJ331439, herein incorporated by reference.) As used herein, the term "SRY (Sex determining Region Y)-box 7" (as well as SOX7) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the SRY (Sex determining Region Y)-box 7 set forth in SEQ ID No:349. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 181.

The gene herein after referred to as "integrin beta 1 subunit" (or alternatively as Integrin Bl) is well-known in the art. (For a non-limiting example, see GenBank Accession X07979, herein incorporated by reference.) As used herein, the term "integrin beta 1 subunit" (as well as Integrin Bl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the integrin beta 1 subunit set forth in SEQ ID No:350. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 182.

The gene herein after referred to as "desmin" (or alternatively as DES) is well-known in the art. (For a non-hmiting example, see GenBank Accession

NM_001927, herein incorporated by reference.) As used herein, the term "desmin" (as well as DES) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the desmin set forth in SEQ ID No:351. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 183.

The gene herein after referred to as "protection of telomeres 1" (or alternatively as POTl, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_015450, herein incorporated by reference.) As used herein, the term "protection of telomeres 1" (as well as POTl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the protection of telomeres 1 set forth in SEQ ID No:352. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in one or more of SEQ ID Nos:"184 and 195.

The gene herein after referred to as "H2.0-hke homeo box 1" (or alternatively as HLXl) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_021958, herein incorporated by reference.) As used herein, the term "H2.0-like homeo box 1" (as well as HLXl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the H2.0-like homeo box 1 set forth in SEQ ID No:353. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 186. The gene herein after referred to as "GABA transport protein" (or alternatively as GABA Transport protein, ) is well-known in the art. (For a non-limiting example, see GenBank Accession U76343, herein incorporated by reference.) As used herein, the term "GABA transport protein" (as well as GABA Transport protein) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the GABA transport protein set forth in SEQ ID No:354. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 187.

The gene herein after referred to as "vmyc myelocytomatosis viral related oncogene neuroblastoma derived" (or alternatively as V-myc or MYCN) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_005378, herein incorporated by reference.) As used herein, the term "v-myc myelocytomatosis viral related oncogene neuroblastoma derived" (as weU as V-myc or MYCN) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the vmyc myelocytomatosis viral related oncogene neuroblastoma derived set forth in SEQ ID No:355. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 188. The gene herein after referred to as "BAG-family molecular chaperone regulator-5" (or alternatively as BAG5) is well-known in the art. (For a non-hmiting example, see GenBank Accession AF095195, herein incorporated by reference.) As used herein, the term "BAG-family molecular chaperone regulator-5" (as well as BAG5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the BAG-family molecular chaperone regulator-5 set forth in SEQ ID No:356. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 189.

The gene herein after referred to as "Human placental bone morphogenic protein" (or alternatively as PLAB) is well-known in the art. (For a non-limiting example, see GenBank Accession U88323, herein incorporated by reference.) As used herein, the term "Human placental bone morphogenic protein" (as well as PLAB) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the Human placental bone morphogenie protein set forth in SEQ ID No:357. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 190.

The gene herein after referred to as "retinoblastoma- associated factor 600" (or alternatively as BAF600, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession AF348492, herein incorporated by reference.) As used herein, the term "retinoblastoma-associated factor 600" (as well as BAF600) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the retinoblastoma-associated factor 600 set forth in SEQ ID No:358. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 191.

The gene herein after referred to as "ALK-4" (or alternatively as ALK-4, ) is well-known in the art. (For a non-limiting example, see GenBank Accession Z22536, herein incorporated by reference.) As used herein, the term "ALK-4" (as well as

ALK-4) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the ALK-4 set forth in SEQ ID No:359. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 192.

The gene herein after referred to as "tolloid-like 2" (or alternatively as TLL2, ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_012465, herein incorporated by reference.) As used herein, the term "tolloid-like 2" (as well as TLL2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the tolloid-like 2 set forth in SEQ ID No:360. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 193.

The gene herein after referred to as "RIGB" (or alternatively as RIGB, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession AF525085, herein incorporated by reference.) As used herein, the term "RIGB" (as well as RIGB) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the RIGB set forth in SEQ ID No:361. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 194.

The gene herein after referred to as "Human DNA repair helicase" (or alternatively as ERCC3) is well-known in the art. (For a non-limiting example, see GenBank Accession M31899, herein incorporated by reference.) As used herein, the term "Human DNA repair helicase" (as well as ERCC3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the Human DNA repair helicase set forth in SEQ ID No:362. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 196.

The gene herein after referred to as "T-box 22" (or alternatively as TBX22) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_016954, herein incorporated by reference.) As used herein, the term "T-box 22" (as well as TBX22) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the T-box 22 set forth in SEQ ID No:363. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 197. The gene herein after referred to as "BRCAl associated protein 1" (or alternatively as BAPl) is well-known in the art. (For a non-hmiting example, see GenBank Accession AF045581, herein incorporated by reference.) As used herein, the term "BRCAl associated protein 1" (as well as BAPl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the BRCAl associated protein 1 set forth in SEQ ID No:364. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 198. The gene herein after referred to as "Sp3 transcription factor" (or alternatively as SP3(J), ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_003111, herein incorporated by reference.) As used herein, the term "Sp3 transcription factor" (as well as SP3(J)) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the Sp3 transcription factor set forth in SEQ ID No:365. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 199.

The gene herein after referred to as "TEF-1 gene" (or alternatively as TEFl(D), ) is well-known in the art. (For a non-limiting example, see GenBank Accession X84839, herein incorporated by reference.) As used herein, the term "TEF-1 gene" (as well as TEFl(D)) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the TEF- 1 gene set forth in SEQ ID No:366. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 201.

The gene herein after referred to as "forkhead box A3" (or alternatively as FOXA3) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_004497, herein incorporated by reference.) As used herein, the term "forkhead box A3" (as well as FOXA3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the forkhead box A3 set forth in SEQ ID No:367. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in one or more of SEQ ID Nos:"202 and 210.

The gene herein after referred to as "ets family transcription factor ELF2A" (or alternatively as ELF2) is well-known in the art. (For a non-limiting example, see GenBank Accession AF256222, herein incorporated by reference.) As used herein, the term "ets family transcription factor ELF2A" (as well as ELF2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the ets family transcription factor ELF2A set forth in SEQ ID No:368. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 203.

The gene herein after referred to as "microtubule-associated protein 1A" (or alternatively as MAPIA) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_002373, herein incorporated by reference.) As used herein, the term "microtubule-associated protein 1A" (as well as MAPIA) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the microtubule-associated protein lAset forth in SEQ ID No:369. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 204.

The gene herein after referred to as "myosin 5B" (or alternatively as Myosin 5B) is well-known in the art. (For a non-limiting example, see GenBank Accession AY274809, herein incorporated by reference.) As used herein, the term "myosin 5B" (as well as Myosin 5B) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the myosin 5B set forth in SEQ ID No:370. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 205.

The gene herein after referred to as "NEDD4Tike ubiquitin ligase 1" (or alternatively as NEDLl) is well-known in the art. (For a non-limiting example, see GenBank Accession AB048365, herein incorporated by reference.) As used herein, the term "NEDD4--hke ubiquitin ligase 1" (as well as NEDLl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the NEDD4-like ubiquitin hgase 1 set forth in SEQ ID No:371. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 206.

The gene herein after referred to as "Mintl mRNA" (or alternatively as MINT1) is well-known in the art. (For a non-limiting example, see GenBank Accession AF029106, herein incorporated by reference.) As used herein, the term "Mintl mRNA" (as well as MINTl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the Mintl mRNA set forth in SEQ ID No:372. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 207.

The gene herein after referred to as "PARX protein" (or alternatively as PARX) is well-known in the art. (For a non-limiting example, see GenBank Accession AF439781, herein incorporated by reference.) As used herein, the term "PARX protein" (as well as PARX) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the PARX protein set forth in SEQ ID No:373. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 208. The gene herein after referred to as "epidermal growth factor receptor" (or alternatively as ERBB3) is well-known in the art. (For a non-limiting example, see GenBank Accession M29366, herein incorporated by reference.) As used herein, the term "epidermal growth factor receptor" (as well as ERBB3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the epidermal growth factor receptor set forth in SEQ ID No:374. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 209.

The gene herein after referred to as "matrix metaUoproteinase 3" (or alternatively as MMP3) is well-known in the art. (For a non-hmiting example, see GenBank Accession AF405705, herein incorporated by reference.) As used herein, the term "matrix metaUoproteinase 3" (as weU as MMP3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the matrix metaUoproteinase 3 (stromelysin 1; progelatinase) set forth in SEQ ID No:375. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 211.

The gene herein after referred to as "VE-cadherin" (or alternatively as VE-CADHERIN) is weU-known in the art. (For a non-limiting example, see GenBank Accession X79981, herein incorporated by reference.) As used herein, the term "VE-cadherin" (as well as VE-CADHERIN) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the VE-cadherin set forth in SEQ ID No:376. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 212.

The gene herein after referred to as "microtubule-associated protein 2" (or alternatively as MAP2) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_002374, herein incorporated by reference.) As used herein, the term "microtubule-associated protein 2" (as well as MAP2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the microtubule-associated protein 2 set forth in SEQ ID No^;377. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 213.

The gene herein after referred to as "TAF7 RNA polymerase II TATA box binding protein (TBP)- associated factor" (or alternatively as TAFII55 or TAF7) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_005642, herein incorporated by reference.) As used herein, the term "TAF7 RNA polymerase II TATA box binding protein (TBP) -associated factor" (as well as TAFII55 or TAF7) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the TAF7 RNA polymerase II TATA box binding protein (TBP) -associated factor set forth in SEQ ID No:378. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No-^" 214.

The gene herein after referred to as "mitochondrial elongation factor G2" (or alternatively as EFG2) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_032380, herein incorporated by reference.) As used herein, the term "mitochondrial elongation factor G2" (as well as EFG2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the mitochondrial elongation factor G2 set forth in SEQ ID No:379. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 215.

The gene herein after referred to as "eyes absent homolog" (or alternatively as Eabl) is well-known in the art. (For a non-hmiting example, see GenBank Accession U71207, herein incorporated by reference.) As used herein, the term "eyes absent homolog" (as well as Eabl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the eyes absent homolog set forth in SEQ ID No:380. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 216.

The gene herein after referred to as "paired box gene 3" (or alternatively as PAX3, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_181457, herein incorporated by reference.) As used herein, the term "paired box gene 3" (as well as PAX3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the paired box gene 3 set forth in SEQ ID No:381. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 217.

The gene herein after referred to as "synaptotagmin I" (or alternatively as Synaptotagminl(D) 3UTR, ) is well-known in the art. (For a non-limiting example, see GenBank Accession U19921, herein incorporated by reference.) As used herein, the term "synaptotagmin I" (as well as Synaptotagminl(D) 3UTR) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the synaptotagmin I set forth in SEQ ID No:382. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 218.

The gene herein after referred to as "histone deacetylase 5" (or alternatively as HDAC5) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_005474, herein incorporated by reference.) As used herein, the term "histone deacetylase 5" (as weU as HDAC5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the histone deacetylase 5 set forth in SEQ ID No:383. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 219.

The gene herein after referred to as "homolog of Drosophila headcase" (or alternatively as hHDC) is well-known in the art. (For a non-hmiting example, see GenBank Accession AB033492, herein incorporated by reference.) As used herein, the term "homolog of Drosophila headcase" (as weU as hHDC) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the homolog of Drosophila headcase set forth in SEQ ID No:384. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 220.

The gene herein after referred to as "homeo box B8" (or alternatively as HOXB8) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_024016, herein incorporated by reference.) As used herein, the term "homeo box B8" (as weU as HOXB8) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the homeo box B8 set forth in SEQ ID No:385. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 221.

The gene herein after referred to as "fyn-related kinase" (or alternatively as FRK, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_002031, herein incorporated by reference.) As used herein, the term "fyn-related kinase" (as weU as FRK) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the fyn-related kinase set forth in SEQ ID No:386. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 222.

The gene herein after referred to as "TGF-beta/activin signal transducer FAST-lp" (or alternatively as FASTI) is weU-known in the art. (For a non-limiting example, see GenBank Accession AF076292, herein incorporated by reference.) As used herein, the term "TGF-beta/activin signal transducer FAST-lp" (as well as FASTI) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the TGF-beta/activin signal transducer FAST-lp set forth in SEQ ID No:387. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 223.

The gene herein after referred to as "La autoantigen" (or alternatively as La antigen, ) is weU-known in the art. (For a non-limiting example, see GenBank Accession X97869, herein incorporated by reference.) As used herein, the term "La autoantigen" (as well as La antigen) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the La autoantigen set forth in SEQ ID No:388. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 224.

The gene herein after referred to as "mutL homolog 1" (or alternatively as MLHl) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_000249, herein incorporated by reference.) As used herein, the term "mutL homolog 1" (as well as MLHl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the mutL homolog 1 set forth in SEQ ID No:389. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 225. The gene herein after referred to as "E74-Uke factor 3" (or alternatively as

ELF3) is well-known in the art. (For a non-hmiting example, see GenBank Accession AF517841, herein incorporated by reference.) As used herein, the term "E74-like factor 3" (as weU as ELF3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the E74-like factor 3 set forth in SEQ ID No:390. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 226.

The gene herein after referred to as "B-myb gene" (or alternatively as B-Myb) is well-known in the art. (For a non-limiting example, see GenBank Accession X13293, herein incorporated by reference.) As used herein, the term "B-myb gene"

(as well as B-Myb) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the B-myb gene set forth in SEQ ID No:391. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in one or more of SEQ ID Nos:"227 and 259.

The gene herein after referred to as "a-myb mRNA" (or alternatively as a-myb) is well-known in the art. (For a non-limiting example, see GenBank Accession X66087, herein incorporated by reference.) As used herein, the term "a-myb mRNA" (as well as a-myb) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the a-myb mRNA set forth in SEQ ID No:392. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 228. The gene herein after referred to as "jagged 1" (or alternatively as JAGl) is well-known in the art. (For a non-Umiting example, see GenBank Accession NM 300214, herein incorporated by reference.) As used herein, the term "jagged 1" (as well as JAGl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the jagged 1 set forth in SEQ ID No:393. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 229.

The gene herein after referred to as "homeobox protein SHOTb" (or alternatively as SHOTb) is well-known in the art. (For a non-limiting example, see GenBank Accession AJ002368, herein incorporated by reference.) As used herein, the term "homeobox protein SHOTb" (as well as SHOTb) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the homeobox protein SHOTb set forth in SEQ ID No:394. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 230.

The gene herein after referred to as "death-associated protein kinase 3" (or alternatively as DAPK3, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_001348, herein incorporated by reference.) As used herein, the term "death-associated protein kinase 3" (as well as DAPK3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the death-associated protein kinase 3 set forth in SEQ ID No:395. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 231.

The gene herein after referred to as "RAD51 homolog" (or alternatively as RecA homolog or RAD51) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_002875, herein incorporated by reference.) As used herein, the term "RAD51 homolog" (as well as RecA homolog or RAD51) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the RAD51 homolog (RecA homolog or RAD51) set forth in SEQ ID No:396. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 232.

The gene herein after referred to as "methyl- CpG binding endonuclease" (or alternatively as MEDl) is weU-known in the art. (For a non-hmiting example, see GenBank Accession AF114784, herein incorporated by reference.) As used herein, the term "methyl- CpG binding endonuclease" (as weU as MEDl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the methyl-CpG binding endonuclease set forth in SEQ ID No:397. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 233.

The gene herein after referred to as "HUSl checkpoint homolog" (or alternatively as HUSl) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_004507, herein incorporated by reference.) As used herein, the term "HUSl checkpoint homolog" (as weU as HUSl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the HUSl checkpoint homolog set forth in SEQ ID No:398. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 234. The gene herein after referred to as "Human homolog of ESI" (or alternatively as HESl (Y07572 ) ) is well-known in the art. (For a non-hmiting example, see GenBank Accession Y07572, herein incorporated by reference.) As used herein, the term "Human homolog of ESI" (as well as HESl (Y07572)) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for Human homolog of ESI set forth in SEQ ID No:399. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: ii.

The gene herein after referred to as "caldesmon 1" (or alternatively as CALDESMON or CALDl) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_033138, herein incorporated by reference.) As used herein, the term "caldesmon 1" (as well as CALDESMON or CALDl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the caldesmon 1 set forth in SEQ ID No:400. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 235.

The gene herein after referred to as "VENT-like homeobox 2" (or alternatively as VENTX2) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_014468, herein incorporated by reference.) As used herein, the term "VENT-like homeobox 2" (as well as VENTX2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the VENT-like homeobox 2 set forth in SEQ ID No:401. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 236.

The gene herein after referred to as "early growth response 2 protein" (or alternatively as EGR2) is well-known in the art. (For a non-Umiting example, see GenBank Accession J04076, herein incorporated by reference.) As used herein, the term "early growth response 2 protein" (as well as EGR2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the early growth response 2 protein set forth in SEQ ID No:402. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 237.

The gene herein after referred to as "Notch3" (or alternatively as NOTCH3, ) is weU-known in the art. (For a non-limiting example, see GenBank Accession U97669 , herein incorporated by reference.) As used herein, the term "Notch3" (as well as NOTCH3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the Notch3 set forth in SEQ ID No:403. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 238. The gene herein after referred to as "lin-28 homolog" (or alternatively as

Lin28, ) is weU-known in the art. (For a non-hmiting example, see GenBank Accession NM_024674, herein incorporated by reference.) As used herein, the term "lin-28 homolog" (as well as Lin28) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the lin-28 homolog set forth in SEQ ID No:404. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 239.

The gene herein after referred to as "PML-3" (or alternatively as PML3) is well-known in the art. (For a non-limiting example, see GenBank Accession M79464, herein incorporated by reference.) As used herein, the term "PML-3" (as well as

PML3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the PML-3 set forth in SEQ ID No:405. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No= 240.

The gene herein after referred to as "c-myc binding protein" (or alternatively as MYCBP, ) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_012333, herein incorporated by reference.) As used herein, the term "c-myc binding protein" (as weU as MYCBP) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the c-myc binding protein set forth in SEQ ID No:406. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 241. The gene herein after referred to as "transducer of ERBB2 1" (or alternatively as TOBl) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_005749, herein incorporated by reference.) As used herein, the term "transducer of ERBB2 1" (as well as TOBl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the transducer of ERBB2 1 set forth in SEQ ID No:407. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 242. The gene herein after referred to as "neuron navigator 3" (or alternatively as NAV3) is weU-known in the art. (For a non-hmiting example, see GenBank Accession NM_014903, herein incorporated by reference.) As used herein, the term "neuron navigator 3" (as well as NAV3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the neuron navigator 3 set forth in SEQ ID No:408. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 243.

The gene herein after referred to as "multiple asters 1" (or alternatively as MASTl) is well-known in the art. (For a non-limiting example, see GenBank Accession AF347693 , herein incorporated by reference.) As used herein, the term "multiple asters 1" (as well as MASTl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the multiple asters 1 set forth in SEQ ID No:409. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 244. The gene herein after referred to as "headcase homolog" (or alternatively as

HECA) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_016217, herein incorporated by reference.) As used herein, the term "headcase homolog" (as well as HECA) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the headcase homolog set forth in SEQ ID No:410. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 245.

The gene herein after referred to as "microtubule-associated protein 6" (or alternatively as MAP6) is well-known in the art. (For a non-hmiting example, see GenBank Accession XM_166256, herein incorporated by reference.) As used herein, the term "microtubule-associated protein 6" (as well as MAP6) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the microtubule-associated protein 6 set forth in SEQ ID No:411. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 246.

The gene herein after referred to as "methyl-CpG binding domain protein 1" (or alternatively as MBDl) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_015846, herein incorporated by reference.) As used herein, the term "methyl- CpG binding domain protein 1" (as well as MBDl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the methyl-CpG binding domain protein 1 set forth in SEQ ID No:412. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 247.

The gene herein after referred to as "EphA5" (or alternatively as EPHA5) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_004439, herein incorporated by reference.) As used herein, the term "EphA5" (as weU as EPHA5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the EphA5 set forth in SEQ ID No:413. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 248. The gene herein after referred to as "polymerase (RNA) III" (or alternatively as RPC32) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_006467, herein incorporated by reference.) As used herein, the term "polymerase (RNA) III" (as well as RPC32) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the polymerase (RNA) III (DNA directed) set forth in SEQ ID No:414. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 249. The gene herein after referred to as "neuro-oncological ventral antigen 1" (or alternatively as NOVAl) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_002515, herein incorporated by reference.) As used herein, the term "neuro-oncological ventral antigen 1" (as well as NOVAl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the neuro-oncological ventral antigen 1 set forth in SEQ ID No:415. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 250.

The gene herein after referred to as "activating transcription factor 1" (or alternatively as ATFl) is well-known in the art. (For a non-hmiting example, see

GenBank Accession NMJD05171, herein incorporated by reference.) As used herein, the term "activating transcription factor 1" (as weU as ATFl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the activating transcription factor 1 set forth in SEQ ID No:416. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 251.

The gene herein after referred to as "interphotoreceptor retinoid-binding protein" (or alternatively as IRBP) is well-known in the art. (For a non-limiting ι example, see GenBank Accession M22453, herein incorporated by reference.) As used herein, the term "interphotoreceptor retinoid-binding protein" (as well as IRBP) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the interphotoreceptor retinoid-binding protein set forth in SEQ ID No:417. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 252.

The gene herein after referred to as "E2F transcription factor 3" (or alternatively as E2F3) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_001949, herein incorporated by reference.) As used herein, the term "E2F transcription factor 3" (as well as E2F3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the E2F transcription factor 3 set forth in SEQ ID No:418. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 253.

The gene herein after referred to as "mesoderm specific transcript homolog" (or alternatively as MEST) is well-known in the art. (For a non-limiting example, see GenBank Accession NMJD02402, herein incorporated by reference.) As used herein, the term "mesoderm specific transcript homolog" (as weU as MEST) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the mesoderm specific transcript homolog set forth in SEQ ID No:419. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 254.

The gene herein after referred to as "bone morphogenetic protein 3" (or alternatively as BMP3) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_001201, herein incorporated by reference.) As used herein, the term "bone morphogenetic protein 3" (as well as BMP3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the bone morphogenetic protein 3 (osteogenic) set forth in SEQ ID No:420. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 255.

The gene herein after referred to as "EphAS" (or alternatively as EPHA3, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_005233, herein incorporated by reference.) As used herein, the term ΕphA3" (as well as EPHA3) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the EphAS set forth in SEQ ID No:421. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 256.

The gene herein after referred to as "methyl-CpG binding domain protein 5" (or alternatively as MBD5) is weU-known in the art. (For a non-Umiting example, see GenBank Accession NMJ318328, herein incorporated by reference.) As used herein, the term "methyl-CpG binding domain protein 5" (as well as MBD5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the methyl-CpG binding domain protein 5 set forth in SEQ ID No:422. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 257.

The gene herein after referred to as "fibroblast growth factor 12" (or alternatively as FGF12) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_021032, herein incorporated by reference.) As used herein, the term "fibroblast growth factor 12" (as well as FGF12) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the fibroblast growth factor 12 set forth in SEQ ID No:423. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 258.

The gene herein after referred to as "RNAheUcase A" (or alternatively as RNA hehcase A) is well-known in the art. (For a non-limiting example, see GenBank Accession L13848, herein incorporated by reference.) As used herein, the term "RNA hehcase A" (as well as RNA helicase A) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the RNA hehcase A set forth in SEQ ID No:424. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 260. The gene herein after referred to as "matrix metaUoproteinase 26" (or alternatively as MMP26) is well-known in the art. (For a non-limiting example, see GenBank Accession NMJD21801, herein incorporated by reference.) As used herein, the term "matrix metaUoproteinase 26" (as weU as MMP26) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the matrix metaUoproteinase 26 set forth in SEQ ID No:425. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 261.

The gene herein after referred to as "crossveinless-2" (or alternatively as Crossveinless-2) is weU-known in the art. (For a non-limiting example, see GenBank Accession AY324650, herein incorporated by reference.) As used herein, the term "crossveinless-2" (as weU as Crossveinless-2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the crossveinless-2 set forth in SEQ ID No:426. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 262.

The gene herein after referred to as "cadherin 5 type 2 VE-cadherin" (or alternatively as CADHERIN5 or CDH5) is well-known in the art. (For a non-limitiiig example, see GenBank Accession NM_001795 , herein incorporated by reference.) As used herein, the term "cadherin 5 type 2 VE-cadherin" (as well as CADHERIN5 or CDH5) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the cadherin 5 type 2 VE-cadherin (vascular epithehum) set forth in SEQ ID No:427. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 263. The gene herein after referred to as "eukaryotic translation initiation factor 4A" (or alternatively as EIF4AI) is weU'known in the art. (For a non-limiting example, see GenBank Accession NMJ301416, herein incorporated by reference.) As used herein, the term "eukaryotic translation initiation factor 4A" (as weU as EIF4AI) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the eukaryotic translation initiation factor 4A set forth in SEQ ID No:428. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 264.

The gene herein after referred to as "TWEAK" (or alternatively as TWEAK) is well-known in the art. (For a non-hmiting example, see GenBank Accession AF030099 , herein incorporated by reference.) As used herein, the term "TWEAK" (as well as TWEAK) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the TWEAK set forth in SEQ ID No:429. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 265.

The gene herein after referred to as "fork head domain protein" (or alternatively as FKHR) is well-known in the art. (For a non-limiting example, see GenBank Accession U02310, herein incorporated by reference.) As used herein, the term "fork head domain protein" (as well as FKHR) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the fork head domain protein set forth in SEQ ID No:430. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 266. The gene herein after referred to as "HOXB7" is well-known in the art. (For a non-limiting example, see GenBank Accession AJ414528, herein incorporated by reference.) As used herein, the term "HOXB7" refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the HOXB7 gene set forth in SEQ ID No:431. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 268.

The gene herein after referred to as "Pax- 3" is weU- known in the art. (For a non-limiting example, see GenBank Accession AJ007392, herein incorporated by reference.) As used herein, the term "Paχ-3" refers to a gene capable of transcribing an mRNA transcript having substantial homology with an rnRNA transcribed from the gene for the Paχ-3 set forth in SEQ ID No:432. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 269. The gene herein after referred to as "homeobox protein SHOTa" (or alternatively as SHOTa) is weU-known in the art. (For a non-limiting example, see GenBank Accession AJ002367, herein incorporated by reference.) As used herein, the term "homeobox protein SHOTa" (as well as SHOTa) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the homeobox protein SHOTa set forth in SEQ ID No:433. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 270.

The gene herein after referred to as "inhibitor of growth famUy member 1" (or alternatively as INGl, ) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_198219, herein incorporated by reference.) As used herein, the term "inhibitor of growth family member 1" (as well as INGl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the inhibitor of growth family member 1 set forth in SEQ ID No:434. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No= 271.

The gene herein after referred to as "vets erythroblastosis virus E26 oncogene like" (or alternatively as V-ETS or ERG) is well-known in the art. (For a non-limiting example, see GenBank Accession NM 304449, herein incorporated by reference.) As used herein, the term "vets erythroblastosis virus E26 oncogene like" (as well as V-ETS or ERG) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the vets erythroblastosis virus E26 oncogene like set forth in SEQ ID No:435. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 272.

The gene herein after referred to as "reticulon 4" (or alternatively as RTN4) is well-known in the art. (For a non-Umiting example, see GenBank Accession NM_020532, herein incorporated by reference.) As used herein, the term "reticulon 4" (as well as RTN4) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the reticulon 4 set forth in SEQ ID No:436. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 273.

The gene herein after referred to as "NOD2 protein" (or alternatively as NOD2) is weU-known in the art. (For a non-limiting example, see GenBank Accession AF178930, herein incorporated by reference.) As used herein, the term "NOD2 protein" (as weU as NOD2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the NOD2 protein set forth in SEQ ID No:437. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 274. The gene herein after referred to as "interleukin 6 receptor" (or alternatively as IL6R) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_000565 , herein incorporated by reference.) As used herein, the term "interleukin 6 receptor" (as well as IL6R) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the interleukin 6 receptor set forth in SEQ ID No:438. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 275.

The gene herein after referred to as "PML-2 mRNA" (or alternatively as PML2) is well-known in the art. (For a non-limiting example, see GenBank Accession M79463, herein incorporated by reference.) As used herein, the term "PML-2 mRNA" (as well as PML2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the PML-2 mRNA set forth in SEQ ID No^:439. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 276.

The gene herein after referred to as "discs large homolog 1" (or alternatively as DLGl) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_004087, herein incorporated by reference.) As used herein, the term "discs large homolog 1" (as well as DLGl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the discs large homolog 1 set forth in SEQ ID No:440. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 277. The gene herein after referred to as 'Yes-associated protein 1" (or alternatively as YAPl) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_006106 , herein incorporated by reference.) As used herein, the term 'Υes-assoeiated protein 1" (as well as YAPl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the Yes-associated protein 1 set forth in SEQ ID No:441. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 278.

The gene herein after referred to as "CD 14 antigen" (or alternatively as CD 14) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_000591, herein incorporated by reference.) As used herein, the term "CD 14 antigen" (as weU as CD 14) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the CD 14 antigen set forth in SEQ ID No:442. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 279.

The gene herein after referred to as "negative differentiation regulator" (or alternatively as NDR) is well-known in the art. (For a non-hmiting example, see GenBank Accession AY255672, herein incorporated by reference.) As used herein, the term "negative differentiation regulator" (as well as NDR) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the negative differentiation regulator set forth in SEQ ID No:443. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 280.

The gene herein after referred to as "CREB binding protein" (or alternatively as CBP or CREBBP) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_004380, herein incorporated by reference.) As used herein, the term "CREB binding protein" (as well as CBP or CREBBP) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the CREB binding protein (RubinsteiirTaybi syndrome) set forth in SEQ ID No:444. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 281.

The gene herein after referred to as "vski sarcoma viral oncogene homolog" (or alternatively as V^_ski or SKI) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_003036, herein incorporated by reference.) As used herein, the term "vski sarcoma viral oncogene homolog" (as well as V-ski or SKI) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the vski sarcoma viral oncogene homolog set forth in SEQ ID No:445. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 282.

The gene herein after referred to as "sidekick homolog 1" (or alternatively as SDKl) is well-known in the art. (For a non-Umiting example, see GenBank Accession NM_152744, herein incorporated by reference.) As used herein, the term "sidekick homolog 1" (as well as SDKl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the sidekick homolog 1 set forth in SEQ ID No:446. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 283.

The gene herein after referred to as "bone morphogenetic protein receptor type II" (or alternatively as BMPR2) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_001204, herein incorporated by reference.) As used herein, the term "bone morphogenetic protein receptor type II" (as well as BMPR2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the bone morphogenetic protein receptor type II set forth in SEQ ID No-'447. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No-" 284.

The gene herein after referred to as "programmed cell death 10" (or alternatively as PDCD10) is well-known in the art. (For a non-hmiting example, see GenBank Accession NMJ307217, herein incorporated by reference.) As used herein, the term "programmed cell death 10" (as well as PDCD10) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the programmed ceU death 10 set forth in SEQ ID No:448. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 285.

The gene herein after referred to as "cyclin H" (or alternatively as CDK7 or CCNH) is weU-known in the art. (For a non-hmiting example, see GenBank Accession NM_001239, herein incorporated by reference.) As used herein, the term "cyclin H" (as well as CDK7 or CCNH) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the cyclin H set forth in SEQ ID No:449. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 286.

The gene herein after referred to as "nuclear protein double minute 1" (or alternatively as MDMl) is well-known in the art. (For a non-hmiting example, see GenBank Accession NM_017440, herein incorporated by reference.) As used herein, the term "nuclear protein double minute 1" (as well as MDMl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the nuclear protein double minute 1 set forth in SEQ ID No:450. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No= 287. The gene herein after referred to as "BCL2/adenovirus E1B 19kDa interacting protein 2" (or alternatively as BNIP2) is weU-known in the art. (For a non-limiting example, see GenBank Accession NM_004330, herein incorporated by reference.) As used herein, the term "BCL2/adenovirus E1B 19kDa interacting protein 2" (as well as BNIP2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the BCL2/adenovirus E1B 19kDa interacting protein 2 set forth in SEQ ID No:451. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 288.

The gene herein after referred to as "karyopherin (importin) beta 2" (or alternatively as Importin beta2) is well-known in the art. (For a non-hmiting example, see GenBank Accession BC040340, herein incorporated by reference.) As used herein, the term "karyopherin (importin) beta 2" (as weU as Importin beta2) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the karyopherin (importin) beta 2 set forth in SEQ ID No:452. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 289. The gene herein after referred to as "vros UR2 sarcoma virus oncogene homolog 1" (or alternatively as V-ros or ROSl) is well-known in the art. (For a non-limiting example, see GenBank Accession NM_002944, herein incorporated by reference.) As used herein, the term "vros UR2 sarcoma virus oncogene homolog 1" (as weU as V-ros or ROSl) refers to a gene capable of transcribing an mRNA transcript having substantial homology with an mRNA transcribed from the gene for the vros UR2 sarcoma virus oncogene homolog 1 set forth in SEQ ID No:453. In a preferred embodiment an mRNA transcribed from said gene comprises an miRNA target region having substantial homology to an miRNA target region set forth in SEQ ID No: 290. As disclosed herein, 100% sequence identity between the RNA and the target gene is not required to practice the present invention. Indeed, among the example of the instant invention, miRNAs having identities sharing as littles as about 50% identity with a corresponding miRNA target region hve been found to effectively modulate expression of a target gene. Thus, RNAs of the invention have the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence.

The present invention provides products and methods for modulating expression of a target gene in a eell. One such method comprises introducing into the cell a polynucleotide that forms a duplex region with an mRNA transcribed from said target gene, wherein the duplex region comprises a mammalian miRNA target region. Another such method comprises introducing into the cell an siRNA that forms a duplex region with an miRNA, or precursor thereof, wherein an mRNA transcribed from the target gene comprises a miRNA target region. In certain preferred embodiments, the methods further comprise measuring expression of the target gene. The method are particularly useful for modulating ontogenesis, function, differentiation and/or viability of a mammalian cell. As such, the invention also provides methods for controlling ontogenesis of mammal, function of mammahan ceU, differentiation of mammalian cell or viability of mammalian ceU in the post-transcriptional phase by introducing into the cell a miRNA or a siRNA silencing precursor to the miRNA. In one embodiment, the invention provides a method for modulating expression of a target gene in a cell, the method comprising introducing into the ceU a polynucleotide that forms a duplex region with an mRNA transcribed from said target gene, wherein said duplex region comprises a mammahan miRNA target region. In a preferred embodiment, the miRNA target region comprises a sequence having at least about 70% identity to a polynucleotide selected from SEQ ID Nos: 5-11, 13, and 121-290. In more preferred embodiments, the miRNA target region comprises a sequence having at least about 80% identity, at least about 90% identity, or at least about 95% identity to a polynucleotide selected from SEQ ID Nos: 5-11, 13, and 121-290. In certain preferred embodiments, the inventive methods employ an miRNA or a precursor thereof, or a vector encoding said miRNA or a precursor thereof for use as a polynucleotide to be introduced into the cell. In certain preferred embodiments, the ceU is a mammalian cell, and preferably a human cell. The ceU may be an isolated cell or may be part of a culture, tissue, or whole multi-ceUular organism. In a preferred embodiment, the miRNA comprises a sequence having at least about 70% identity to a polynucleotide selected from SEQ ID Nos: 1, 3, 12, and 14-120. In more preferred embodiments, the miRNA comprises a sequence having at least about 80% identity, at least about 90% identity, or at least about 95% identity to a polynucleotide selected from selected from SEQ ID Nos: 1, 3, 12, and 14-120. Particularly preferred embodiments of miRNAs for use in the inventive method include miR-1, miR-2-1, miR-5, miR-7, miR-8, miR- 11, miR- 12, miR- 13, miR- 14, miR-15, miR-16, miR- 17, miR-18, miR-19, miR-20, miR-21, miR-22, miR-23, miR-24,miR-25, miR-26, miR-27, miR-28, miR-29, miR-30, miR-31, miR-32, miR-33, miR-34, miR-92, miR-93, miR-94, miR-95, miR-96, miR-97, miR-98, miR-99, miR- 100, miRlOl, miR- 103, miR- 104, miR- 105, miR- 106 , miR- 107, miR- 109, miR- 110, miR- 111, miR- 112, miR-113,miR-114,miR-116, miR- 119, miR- 122, miR- 125, miR- 126, miR- 127, miR- 129, miR- 130, miR- 132 , miR- 133 , miR- 134 , miR- 136 , miR- 138 , miR- 140, miR- 141, miR- 144, miR- 145, miR- 146, miR- 147, miR- 148, miR- 149, miR- 150, miR- 151, miR- 153, miR- 154, miR- 157, miR- 158, miR- 160, miR- 162, miR- 164, miR- 172, miR- 173, miR- 174, miR- 175, miR- 176, miR- 177, miR- 178, miR- 179, miR- 180, miR- 182, miR- 183, miR- 184, miR- 185, miR-186, miR- 187, miR- 188, miR- 189, miR-191, miR- 192, miR- 193, miR- 195, miR- 196, miR- 197, miR- 199, miR-201, miR-203, miR-205, and miR-224., or a precursor thereof. Preferred embodiments of the inventive methods include those for modulating expression of a target gene in a cell, wherein the target gene is one or more of: dbl proto-oncogene; transforming growth factor beta 1; transforming growth factor alpha; vmyb myeloblastosis viral oncogene homolog; c-cbl proto-oncogene; snol; activin beta E subunit; myogenic factor 5; fibroblast growth factor 9; RON encoding a tyrosine kinase; E3 ubiquitin hgase SMURFl; jagged 2; jun-B encoding the JUN-B protein; methyl- CpG binding domain protein 4; ZIP kinase; endomucin,' ICE -protease activating factor; hairy and enhancer of split l; transforming growth factor beta 3; enaptin mRNA; AMP deaminase; interleukin 1 alpha; E2F transcription factor 6; laminin alpha! polymerase (DNA-directed) alpha; leukocyte tyrosine kinase; homeo box Dl; laminin gamma; tumor necrosis factor receptor superfamUy member 1A; viUin 2; frizzled homolog 5; ATP-dependent chromatin remodeUing protein! MSX2 mRNA for transcription factor; adipose differentiation-related protein; myogenic factor 4,^* SRY (Sex determining Region Y)-box 5>^* Notch homolog 1; Human tyrosine kinase-type receptor! polymerase (DNA directed) theta; cAMP responsive element binding protein 3; timeless homolog! RAD52 homolog,' toU-like receptor 4! SRY (Sex determining Region Y)-box 9! homeo box A5! ceU division cycle 42 GTP binding protein; desmuslin,^" TFIIIC Box B-binding subunit; profilin 2,' c-fms proto-oncogene," delta-like 1," fatty-acid-Coenzyme A ligase long-chain 5; discs large homolog-associated protein 2; TFIIH gene for transcription factor II H; RNA polymerase III subunit RPC; RecQ protein- like 5; METH2 protein; MOST2 protein,' SRY (Sex determining Region Y)-box 7; integrin beta 1 subunit," desmin; protection of telomeres 1,^' H2.0-Uke homeo box V, GABA transport protein,' vmyc myelocytomatosis viral related oncogene neuroblastoma derived," BAG-family molecular chaperone regulator-5; Human placental bone morphogenic protein; retinoblastoma-associated factor 600," ALK-4," tolloid-like 2! RIGB; Human DNA repair helicase; T-box 22! BRCAl associated protein l! Sp3 transcription factor! TEF-1 gene," forkhead box A3; ets famUy transcription factor ELF2A; microtubule-associated protein 1A; myosin 5B>' NEDD4-like ubiquitin ligase l; Mintl mRNA; PARX protein; epidermal growth factor receptor; matrix metaUoproteinase 3,^" VE-cadherin,' microtubule-associated protein 2,' TAF7 RNA polymerase II TATA box binding protein (TBP) -associated factor," mitochondrial elongation factor G2," eyes absent homolog," paired box gene 3,^" synaptotagmin I,^" histone deacetylase 5; homolog of Drosophila headcase," homeo box B8," fyn-related kinase," TGF-beta/activin signal transducer FAST-lp; La autoantigen," mutL homolog 1; E74Tike factor 3; B-myb gene! a-myb mRNA," jagged 1," homeobox protein SHOTb," death-associated protein kinase 3; RAD51 homolog (RecA homolog); methyl-CpG binding endonuclease,' HUSl checkpoint homolog! HESl protein! caldesmon 1,^" VENT-like homeobox 2," early growth response 2 protein," Notch3; lin-28 homolog," PML-3," c-myc binding protein,^" transducer of ERBB2 1," neuron navigator 3," multiple asters 1,^" headcase homolog," microtubule-associated protein 6," methyl-CpG binding domain protein 1,' EphAδ; polymerase (RNA) III (DNA directed); neuro-oncological ventral antigen 1," activating transcription factor 1; interphotoreceptor retinoid-binding protein,' E2F transcription factor 3; mesoderm specific transcript homolog,' bone morphogenetic protein 3; EphA3; methyl-CpG binding domain protein 5! fibroblast growth factor 12; RNA helicase A," matrix metaUoproteinase 26," crossveinless-2,' cadherin δ type 2 VE-cadherin; eukaryotic translation initiation factor 4A; TWEAK; fork head domain protein; HOXB7 gene,' Paχ-3," homeobox protein SHOTa," inhibitor of growth family member 1," vets erythroblastosis virus E26 oncogene hke," reticulon 4," NOD2 protein," interleukin 6 receptor; PML-2 mRNA," discs large homolog 1,^" Yes-associated protein 15 CD14 antigen," negative differentiation regulator,' CREB binding protein,' vski sarcoma viral oncogene homolog," sidekick homolog l; bone morphogenetic protein receptor type II," programmed ceU death 10,' cyclin H>' nuclear protein double minute V, BCL2/adenovirus E1B 19kDa interacting protein 2," karyopherin beta 2," and vros UR2 sarcoma virus oncogene homolog 1. In a preferred embodiment, the gene target of the method comprises a polynucleotide sequence that hybridizes under moderately stringent conditions with a polynucleotide sequence selected from SEQ ID Nos: 291-454.

It is particularly preferred that the mRNA transcribed from said target gene comprises a polynucleotide sequence having at least 70% identity to a polynucleotide selected from SEQ ID Nos: 5-11, 13, and 121-290. However, the method contemplates mRNA molecules having miRNA target sequences other than those set forth in 5-11, 13, and 121-290.

In another inventive method for modulating expression of a mammahan target gene in a ceU contemplated by the instant invention, an siRNA that forms a duplex region with an miRNA, or precursor thereof, is introduced into a cell comprising an mRNA transcribed from a target gene, where the target gene comprises an miRNA target region. In preferred embodiments of the inventive method, the siRNA forms a duplex region with an miRNA. The resulting duplex may result in, for example, inhibiting the miRNA from forming a second duplex region with mRNA transcribed from said target gene. It is particularly preferred that the siRNA forms a duplex region with an miRNA precursor, thereby inhibiting the miRNA precursor from converting to miRNA. In certain embodiments, the miRNA or precursor thereof comprises a sequence having at least about 70% identity to a polynucleotide selected from SEQ ID Nos: 1, 3, 12, and 14-120. Among the especially preferred embodiments are those in which wherein the miRNA target region of the method comprises a sequence having at least about 70% identity to a polynucleotide selected from SEQ ID Nos: 5-11, 13, and 121-290.

Contemplated methods include those in which the siRNA target is one or more of: miR-1, miR-2-1, miR-5, miR-7, miR-8, miR-11, miR- 12, miR-13, miR- 14, miR-15, miR- 16, miR- 17, miR- 18, miR- 19, miR-20, miR-21, miR-22, miR-23, miR-24,miR-25, miR-26, miR-27, miR-28, miR-29, miR-30, miR-31, miR-32, miR-33, miR-34, miR-92, miR-93, miR-94, miR-95, miR-96, miR-97, miR-98, miR-99, miR-100, miRlOl, miR- 103, miR- 104, miR- 105, miR- 106 , miR- 107, miR- 109, miR- 110, miR- 111, miR- 112, miR-113,miR-114,miR-116, miR- 119, miR- 122, miR- 125, miR- 126, miR- 127, miR- 129, miR- 130, miR- 132 , miR- 133 , miR- 134 , miR- 136 , miR- 138 , miR- 140, miR- 141, miR-144, miR- 145, miR- 146, miR- 147, miR- 148, miR- 149, miR-150, miR-151, miR-153, miR-154, miR-157, miR-158, miR- 160, miR- 162, miR- 164, miR- 172, miR-173, miR-174, miR- 175, miR- 176, miR- 177, miR- 178, miR- 179, miR- 180, miR- 182, miR- 183, miR- 184, miR- 185, miR-186, miR- 187, miR- 188, miR- 189, miR-191, miR- 192, miR- 193, miR- 195, miR-196, miR- 197, miR- 199, miR-201, miR-203, miR-205, and miR-224., or a precursor thereof. miRNA or precursor thereof comprising a sequence selected from the group consisting of SEQ ID Nos: _t 3_: 12, and 14-120 is especially preferred.

In certain embodiments of the inventive methods employing an siRNA that forms a duplex region with an miRNA, or precursor thereof, a preferred target gene is includes one or more of: dbl proto-oncogene," transforming growth factor beta 1," transforming growth factor alpha! v-myb myeloblastosis viral oncogene homolog! c-cbl proto-oncogene! snol! activin beta E subunit! myogenic factor 5! fibroblast growth factor 9! RON encoding a tyrosine kinase! E3 ubiquitin ligase SMURFl! jagged 2," jun-B encoding the JUN-B protein,' methyl-CpG binding domain protein 4," ZIP kinase," endomucin; ICE -protease activating factor," hairy and enhancer of split 1! transforming growth factor beta 3," enaptin mRNA; AMP deaminase,' interleukin 1 alpha,^' E2F transcription factor 6," laminin alpha,' polymerase (DNA-directed) alpha,' leukocyte tyrosine kinase," homeo box Dl," laminin gamma," tumor necrosis factor receptor superfamily member 1A," villin 2! frizzled homolog 5," ATP-dependent chromatin remodeUing protein," MSX2 mRNA for transcription factor; adipose differentiation-related protein! myogenic factor 4," SRY (Sex determining Region Y)-box 5," Notch homolog 1," Human tyrosine kinase-type receptor," polymerase (DNA directed) theta; cAMP responsive element binding protein 3," timeless homolog," RAD52 homolog,' tolkUke receptor 4; SRY (Sex determining Region Y) -box 9," homeo boxAδ," cell division cycle 42 GTP binding protein,^" desmuslin," TFIIIC Box B-binding subunit," profiUn 2," c-fms proto-oncogene," delta-like 1; fatty-acid-Coenzyme A ligase long-chain 5," discs large homolog-associated protein 2J TFIIH gene for transcription factor II H," RNA polymerase III subunit RPC; RecQ protein-like 5; METH2 protein," MOST2 protein; SRY (Sex determining Region Y) -box 7," integrin beta 1 subunit; desmin,' protection of telomeres 1! H2.0-hke homeo box 1! GABA transport protein! vmyc myelocytomatosis viral related oncogene neuroblastoma derived! BAG-family molecular chaperone regulator-5! Human placental bone morphogenic protein! retinoblastoma-associated factor 600! ALK-4," toUoid-like 2," RIGB,' Human DNA repair helicase! T-box 22! BRCAl associated protein 1! Sp3 transcription factor! TEF-1 gene! forkhead box A3! ets family transcription factor ELF2A; microtubule-associated protein 1A," myosin 5B,"

NEDD4"like ubiquitin hgase 1," Mintl mRNA," PARX protein," epidermal growth factor receptor," matrix metaUoproteinase 3! VE-cadherin! microtubule-associated protein 2! TAF7 RNA polymerase II TATA box binding protein (TBP)-associated factor! mitochondrial elongation factor G2," eyes absent homolog! paired box gene 3! synaptotagmin I," histone deacetylase 5! homolog of Drosophila headcase! homeo box B8! fyn-related kinase," TGF-beta/activin signal transducer FAST-lp; La autoantigen; mutL homolog l; E74-like factor 3," B-myb gene; a-myb mRNA; jagged 1," homeobox protein SHOTb; death-associated protein kinase 3," RADδl homolog (RecA homolog)," methyl-CpG binding endonuclease; HUSl checkpoint homolog," HESl protein," caldesmon 1; VENT-like homeobox 2; early growth response 2 protein; Notch3; Un-28 homolog,' PML-3," c-myc binding protein," transducer of ERBB2 l; neuron navigator 3," multiple asters 1," headcase homolog; microtubule-associated protein 6," methyl-CpG binding domain protein 1,^" EphAδ," polymerase (RNA) III (DNA directed); neuro-oncological ventral antigen 1; activating transcription factor 15 interphotoreceptor retinoid-binding protein,^" E2F transcription factor 3; mesoderm specific transcript homolog,' bone morphogenetic protein 3,' EphA3," methyl-CpG binding domain protein 5; fibroblast growth factor 12," RNA helicase A; matrix metaUoproteinase 26; crossveinless-2; cadherin 5 type 2 VE-cadherin,' eukaryotic translation initiation factor 4A; TWEAK," fork head domain protein," HOXB7 gene,' Paχ-3; homeobox protein SHOTa," inhibitor of growth family member 1,' vets erythroblastosis virus E26 oncogene like,' reticulon 4; NOD2 protein," interleukin 6 receptor; PML-2 mRNA," discs large homolog 1," Yes-associated protein 1," CD 14 antigen," negative differentiation regulator," CREB binding protein," vski sarcoma viral oncogene homolog," sidekick homolog 1," bone morphogenetic protein receptor type II; programmed cell death 10,' cyclin H; nuclear protein double minute 1; BCL2/adenovirus E1B 19kDa interacting protein 2; karyopherin beta 2; and vros UR2 sarcoma virus oncogene homolog 1.

Preferred embodiments include those in which the target gene comprises a polynucleotide sequence that hybridizes under moderately stringent conditions with a polynucleotide sequence selected from SEQ ID Nos: 291-454. It is especially preferred that the mRNA transcribed from the target gene comprises a polynucleotide sequence having at least about 70% identity to a polynucleotide selected from SEQ ID Nos: i_} 3, 12, and 14-120. The methods of the invention may additionally comprise measuring expression of said target gene.

As one of skill in the art would recognize, the inventive methods of the apphcation may be employed to accomphsh a variety of objectives. For example, the methods may be used to modulate ontogenesis, function, differentiation and/or viabUity of a mammalian cell. As such, the invention contemplates methods for controlling ontogenesis of mammal, function of mammaUan ceU, differentiation of mammalian cell or viability of mammalian ceU in the post-transcriptional phase, the methods comprising introducing into the ceU a miRNA or an siRNA sUencing precursor to an endogenous or heterologous miRNA. By way of example, methods of the instant invention may be employed to control differentiation of nerve cell by regulating expression of hairy and enhancer of split 1.

Where an siRNA is introduced into the ceU, one preferred embodiment contemplates the siRNA binding to a loop in stem- loop structure of an miRNA or precursor thereof. In such methods, it is preferred that siRNA has a sequence with at least about 70% identity to the sequence disclosed in SEQ ID No: 2. However, siRNAs prepared to to target other miRNA are also contemplated. Contemplated targets include, for example, miR-1, miR-2-1, miR-5, miR-7, miR-8, miR-11, miR- 12, miR-13, miR-14, miR- 15, miR- 16, miR- 17, miR- 18, miR- 19, miR-20, miR-21, miR-22, miR-23, miR-24,miR-25, miR-26, miR-27, rniR-28, miR-29, miR-30, miR-31, miR-32, miR-33, miR-34, miR-92, miR-93, miR-94, miR-9δ, miR-96, miR-97, miR-98, miR-99, miR-100, miRlOl, miR- 103, miR- 104, miR- 105, miR- 106 , miR- 107, miR- 109, miR-110, miR- 111, miR- 112, miR-113,miR-114,miR-116, miR- 119, miR- 122, miR- 125, miR- 126, miR- 127, miR- 129, miR- 130, miR- 132 , miR- 133 , miR- 134 , miR- 136 , miR-13 8 ,miR-140, miR- 141, miR- 144, miR- 145, miR- 146, miR- 147, miR- 148, miR- 149, miR-150, miR-151, miR-153, miR-154, miR- 157, miR-158, miR-160, miR- 162, miR- 164, miR-172, miR- 173, miR- 174, miR- 175, miR- 176, miR-177, miR- 178, miR- 179, miR-180, miR- 182, miR- 183, miR- 184, miR- 185, miR-186, miR- 187, miR- 188, miR- 189, miR-191, miR- 192, miR- 193, miR- 195, miR- 196, miR- 197, miR- 199, miR-201, miR-203, miR-205, and miR-224., and precursors thereof. Furthermore, it is preferred that siRNA has a sequence with at least about have substantial homology with a contemplated target sequence found in an miRNA or precursor thereof.

The invention further contemplates plasmid vectors comprising a promoter δ and a polynucleotide sequence expressing miRNA or a precursor to the miRNA. Also contemplated are plasmid vectors comprising a promoter and a nucleotide sequence expressing siRNA sUencing precursor to miRNA. With respect to vectors encoding siRNA, it is especially preferred that such vectors encode miRNA that is capable of forming a duplex region with an mRNA transcribed from a mammalian target gene. 10 Promoters selected from the group consisting of tRNA^{( al)} promoter, U6 promoter, HI promoter and Pol II promoter, such as CMV and SV40, are especiaUy preferred.

The invention contemplates methods employing the use of the contemplated vectors for controlhng ontogenesis of mammal, function of mammalian ceU, differentiation of mammalian cell or viabUity of mammalian, the methods comprising Iδ introducing into the cell a contemplated plasmid vector.

Furthermore, the invention contemplates methods for treating cancer, immune disease, nerve disorder or inflammatory disease, the methods comprising introducing into a cell an miRNA, a siRNA sUencing precursor to the miRNA or the plasmid vector as described herein. A particularly preferred method comprises 20 treating a nerve disorder selected from amyotrophic lateral sclerosis (ALS), Parkinson disease or Alzheimer disease.

The invention provides for methods useful in screening pharmaceuticals using an miRNA, an siRNA silencing precursor to the miRNA or the plasmid vector defined, the methods employing the vectors as described herein. It is particularly preferred that the target mRNA is derived from a recombinant gene having a sequence of the target region of the miRNA.

Especially preferred methods are those for gene function analysis using a miRNA, a siRNA silencing precursor to the miRNA or the plasmid vector defined as described herein. Other preferred methods include those for regulation of cell differentiation to muscle cell, bone cell or myocardial cell, where the gene to be regulated is a gene whose function is identified by the gene function analysis as described herein. Also contemplated are methods for preservation or maintenance of anaplastic ceU, introducing into cell a substance suppressing expression of miR-23; methods for regulating ratio of gene expression, by producing recombinant of selected gene and target sequence of miR-23 of Hesl, and designing miR-23 sequence δO to 90% complementary to the target sequence,' methods for suppressing gene expression, the method comprising introducing into ceU an siRNA inducing decomposition of mRNA and a miRNA, such as, for example, miR-23.

EXAMPLES The invention is further described by example. The examples, however, are provided for purposes of illustration to those skUled in the art, and are not intended to be hmiting. Moreover, the examples are not to be construed as hmiting the scope of the appended claims. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and aU variations that become evident as a result of the teaching provided herein.

Hesl is a target of miR-23 in NT2 ceUs It has been reported that some of the Drosophila miRNAs that align to the K box motif (5'-UGUGAU-3') mediate a negative post-transcriptional regulation of the

Hairy/enhancer of spht (HES) gene family in Drosophila²⁸'³⁰. A human miR-23 containing the antisense sequence to the K box motif has also been identified, although its target gene is unknown.

We initiated a study to investigate whether the human Hairy HES gene was the target of human miR-23. Hairy HESl (Accession No. NM_005δ24)³¹ is a basic helix-loop -helix (bHLH) transcriptional repressor that is expressed in undifferentiated ceUs but not in differentiated cells^32"34. It participates in the Notch signahng pathway in mammals and acts as an anti-differentiation factor. miR-23 aUgned to a coding region of human HESl (NM_O0δδ24) mRNA near the termination codon and to mouse Hesl mRNA (NM_008235) at nearly the same position as in human HESl including the stop codon (Fig. la). A duplex of HESl (NM_005524) mRNA and miR-23 was also observed using a prediction program for mRNA secondary structure (Mulfold) suggesting that miR-23 may be conserved phylogeneticaUy as a regulator of human and mouse Hesl. In addition, we also showed that miR-23 forms partial base-pairing with another mRNA simUarly called HESl Y07δ72 (human homolog of Escherichia coli and Zebra sh, Accession No. Y07δ72)³⁵ at nearly the same position as in human HESl (NM_00δδ24) and mouse HESl (NMJ308235) including the stop codon. A protein related to HESl Y07572 with the same ElbB domain is involved in an early stage of the biosynthesis of isoprenoid compounds. Although Hairy HESl (NM_00δδ24) has no similarity to Homolog HESl Y07δ72) at the amino acid level, the target sequences for miR-23 in both genes have 70% simUarity at the mRNA level.). In addition, we found two other independent target sites of miR-23 in the 3'-untranslated region (UTR) of Hairy HESl (NM_005524) mRNA, which are designated motifs II and III (Fig. lb). Moreover, we considered phylogenetic conservation between human and mouse Hairy Hesl as a target of miR-23. The target of mouse Hairy Hesl mRNA (nearly the same position as human Hesl including the stop codon) exhibited significant complementarity (74 %) to mouse miR-23b (Fig. la). A duplex of Hairy Hesl and miR23 was observed using a prediction program of mRNA secondary structure (Mulfold). Thus, this observation suggests that the function of miR-23 is phylogeneticaUy conserved as a regulator of human and mouse Hairy Hesl.

To confirm whether Hairy HESl mRNA might be a target of miR-23, we used human NT2 cells, which are human embryonal carcinoma (EC) ceUs and differentiate into neural cells upon treatment with retinoic acid (RA)³⁶. We first examined the expression of Hairy HESl during RA-induced differentiation by Western blotting and amplified ELISA assay. NT2 cells were treated with RA (δ μM) for 3 weeks. As shown in Figure lc, Hairy HESl was easily detectable in undifferentiated NT2 cells. By contrast, Hairy HESl was barely detectable in differentiated NT2 cells. However, as indicated by Northern blotting analysis, the level of Hairy HESl mRNA in both nuclear (N) and eytoplasmic (C) fraction of cells remained unchanged during RA-induced differentiation (Fig. Id). Moreover, in a sucrose sedimentation assay, an association between Hairy HESl mRNA and polyribosomes was detected in both undifferentiated and differentiated NT2 cells (data not shown). Similar observations have been reported in the case of lin-4"-lin-14 in C. elegans¹⁹-²⁰. These results suggest that the expression of Hairy HESl might be regulated not at the eytoplasmic transport of Hairy HESl mRNA but at the translation level during differentiation of NT2 cells. Next we examined the level of miR-23 during RA-induced differentiation by Northern blotting analysis. As shown in Figure le, miR-23 was barely detectable in undifferentiated NT2 cells but was easily detected in differentiated NT2 cells. These results suggest that expression of miR-23 might be related to differentiation of NT2 ceUs.

Regulation of expression of Hairy HESl gene by miR-23

Next, to examine whether expression of the gene for Hesl is regulated by miR-23, we introduced synthetic single stranded miR-23 or double stranded miR-23 (Fig. 2c) into undifferentiated NT2 cells. When synthetic miR-23 was introduced at 100 nM into undifferentiated NT2 ceUs, the intracellular level of Hesl fell significantly (Fig. 2d). In addition, double stranded miR-23 has high efficiency compared with single stranded miR-23 in mammahan cells (Fig. 2c). By contrast, in the presence of synthetic mutant miR-23, the level of Hesl in undifferentiated NT2 cells remained unchanged and similar to that in untreated wild-type (WT) NT2 cells (Fig. 2b). In addition, the level of Hesl mRNA remained constant irrespective of the presence or absence of either synthetic miR-23 or mutant miR-23 (Fig. 2d). Similar results were obtained using pol III promoter (U6 and tRNApromoter)-dependent miRNA expression system (Fig. b). These results further suggest that synthetic miR-23 might suppress the expression of the gene for Hesl at the translational level. To examine the function of miR-23 in further detail, we tried to reduce the level of endogenous miR-23 using synthetic siRNA (siRNA- miR- 23) targeted to a loop region of the precursor to miR-23 (Fig. 2e). siRNAs can induce the RNA interference -mediated (RNArmediated) sequence-specific sUencing of gene expression in mammalian ceUs³⁷-³⁸. RNAi refers to the sequence-specific sUencing of gene expression that is induced by double-stranded RNAs (dsRNAs) in animals and plants³⁹-⁴⁰. When 100 nM synthetic siRNA-miR-23 was introduced into differentiated NT2 cells, the intraceUular level of precursor and mature miR-23 fell significantly (Fig. 2f). By contrast, the level of Hesl protein increased in the presence of siRNA-miR-23 (Fig. 2g). Importantly, mutant siRNA-miR-23 (Fig. 2e) did not affect expression of miR-23 or the level of Hesl in NT2 ceUs. Moreover, the level of Hesl mRNA was unaffected by synthetic siRNA-miR-23 (Fig. 2h). Similar results were obtained using pol III promoter (U6 and tRNA promoter) -dependent siRNA expression system that targeted to miRNAs (Fig. 2f and 2g). These results indicate that the synthetic siRNA-miR-23 interfered with the function of miR-23 and, as a result, it promoted the accumulation of Hesl protein. These results strengthen our hypothesis that miR23 regulates the expression of Hesl at the post-transcriptional level.

Target specificity of miR-23 in NT2 cells We thus examined whether the intact Hairy HESl (NMJ305524) 3'-UTR can confer regulation on a reporter gene in response to endogenous miR-23 in NT2 cells. To examine the target specificity of miR-23, we constructed plasmids for expression of a chimeric gene for luciferase that was fused 3'-UTR including the sequence of the three potential target motifs of miR-23 in Hairy HESl mRNA (Luc-TM23; Fig. 3a). As a control, we designed the chimeric gene for luciferase that included the sequence of the mutated target motiffe) of miR-23 in Hairy HESl mRNA (Luc-mutant TM23, Luc-mutant motif I, Luc-mutant motif II and Luc-mutant motif III; Fig. 3a). Then we transiently introduced each plasmid into NT2 ceUs. After incubation for 72 h, cells were harvested and lysed. Total proteins were used for the assays of luciferase activity using a luminometer (Lumat LB9δ01,' Berthold, Bad Wildbad, Germany). As shown in Figure 3b, we detected luciferase activity in undifferentiated NT2 ceUs (-RA) that expressed the gene for Luc-TM23. By contrast, the luciferase activity in differentiated cells (+RA) that expressed the gene for Luc-TM23 was significantly lower than that in undifferentiated cells (Fig. 3b). The luciferase activity in cells that expressed Lucmutant TM23 did not changed during the differentiation. These results, under the conditions of natural endogenous level of miR-23, are in accord with the results with Hes 1. In addition, disruption of one target motif of miR-23 weakened the reduction level of the luciferase activity, suggesting the synergistic interaction of miR-23 with these three target sites.

Additionally, the luciferase activity of Luc-TM23 in undifferentiated NT2 cells that had been treated with synthetic miR-23 was significantly lower than that in untreated WT NT2 cells (Fig. 3c). Mutant miR-23 did not affect the luciferase activity of the natural TM23-containing (the intact Hairy HESl S'-UTR-containing) Luc-TM23 cells. By contrast, the luciferase activity in cells that expressed Luc-mutant TM23 remained the same in the presence or absence of synthetic miR-23 and in the presence of mutant miR-23. In addition, in the presence of synthetic miR-23, the luciferase activity in cells that expressed luciferase gene that has one mutant target motif of miR-23 was partiaUy reduced. Moreover, the luciferase activity in differentiated NT2 ceUs that had been treated with synthetic siRNA-miR-23 was higher than that in WT differentiated NT2 cells (Fig. 3d). These results suggest that the regulation of translation by the physiological level of miR-23 can be monitored by the attachment of its natural target UTR to the gene for luciferase and demonstrated that three independent target motifs in Hairy HESl mRNA are certainly targets of miR-23.

Next, to examine the target specificity of miR-23, we constructed plasmids for expression of a chimeric gene for luciferase that was fused 3'-UTR sequence including the target sequence of miR-23 in Homolog HESl mRNA (Luc-TS23," Fig. 3e). As a control, we designed the chimeric gene for luciferase that was fused 3'-UTR sequence including the mutated target site of miR-23 in HESl mRNA (Luc-mTS23," Fig. 3e). Then we introduced each plasmid into NT2 ceUs and obtained stable cell lines after selection with puromycin. As shown in Figure 3b, we detected luciferase activity in undifferentiated NT2 cells that expressed the gene for Luc-TS23. By contrast, the luciferase activity in differentiated ceUs that expressed the gene for Luc-TS23 was lower than that in undifferentiated cells (Fig. 3f). AdditionaUy, the luciferase activity of Luc-TS23 in undifferentiated NT2 cells that had been treated with synthetic miR-23 was lower than that in untreated WT NT2 ceUs (Fig. 3g). Mutant miR-23 did not affect the luciferase activity of natural TS23-containing Luc-TS23 cells. To our surprise, a single-stranded mutant miR-23 RNA with appropriate compensatory mutations that restores its pairing to the mTS23 site (but retains the sites of mismatch, as shown at the mutant miR-23 region in Fig. 3h) rescued translational control of the mTS-luciferase (Fig. 3g), suggesting the possibility to create artificial microRNAs with slightly altered target sequences in the regulation of an arbitrarily chosen target gene. Moreover, the luciferase activity in differentiated NT2 ceUs that had been treated with synthetic siRNA-miR-23 was higher than that in WT differentiated NT2 cells (Fig. 3h). These results suggest that three TM23-I, -II and -III in Hairy HESl (NM_005524) mRNA and TS23 in Homolog HESl (Y07572) mRNA are a target of miR-23 and that the natural near complementarity of TS23 to miR-23 is necessary for miR-23-mediated post-transcriptional silencing of gene expression.

The role of miR-23 during RA-induced neuronal differentiation

To examine the role of miR-23 during RA-induced neuronal differentiation of NT2 cells, we examined a phenotype of NT2 cells grown in the presence or absence of synthetic siRNA-miR-23 by immuno-staining with SSEA-3- and MAP2-specific antibodies. SSEA-3 is expressed only in undifferentiated NT2 ceUs and MAP2 is expressed only in differentiated NT2 cells⁴¹-⁴². Wild-type NT2 cells differentiate into neural ceUs upon treatment with RA (Fig. 4a," left panel). However, in the presence of siRNA-miR-23, NT2 cells did not differentiate into the neural ceUs after treatment with RA (Fig. 4a,^" middle panel). In addition, the level of MAP2, a differentiation marker, did not increase after the cells were treated with synthetic siRNA-miR-23, even though the level of MAP2 increased in WT differentiated NT2 ceUs (Fig. 4b). Accordingly, the level of SSEA-3, a marker of undifferentiated eeUs, did not decrease when NT2 cells were treated with synthetic siRNA-miR-23 and RA (Fig. 4c). However, the addition of synthetic miR-23 to ceUs that contained siRNA-miR-23 was able to reverse the effects of siRNA-miR-23, and these cells differentiated into neural cells upon treatment with RA (Fig. 4a; right panel), with an accompanying reduction in the level of SSEA-3 and induction of MAP2 expression. These results suggest that miR-23 plays a critical role during RA-induced neuronal differentiation.

Identification of target genes of other miRNAs in mammahan ceUs

To understand function of miRNA in mammalian cell, we identified target genes of other miRNAs (more than 100 miRNAs) using BLAST search program (Table l). Many differentiation (myeloid, myogenic, osteogenic and adipogenic)-associated factors are involved in these target genes. For example, expression of HOXB8 that is target of miR- 196 is regulated in myeloid differentiation of HL60 cells. In addition, Myf-δ (target of miR-13) and Myf-4 (target of miR-97) are participate in myogenic differentiation. Moreover, TGF-beta (target of miR- 13) and BMP3 (target of miR- 154) associate with an osteogenic differentiation. Expression of these identified target genes were significantly reduced by synthetic and vector based miRNAs (Fig. 5). Since miRNA and siRNA (target to miRNAs) expression vector can regulate expression of above miRNAs, these expression vector have a high potential for regulation of differentiation and development of mammahan cells.

Culture and transfection o£ ceUs

Human NT2 ceUs were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Transfections were performed with the Effectin™ reagent (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. Luc-TS23-expressing and Luc-mTS23^_expressing NT2 cells were selected by incubation with puromycin for a week. Retinoic acid was used at 5 μM to be induced neuronal differentiation of NT2 cells for 3 weeks.

Preparation of miRNAs and siRNAs

Synthetic miR-23, mutant miR-23 and siRNAs directed against miR-23 were synthesized with a DNA/RNA synthesizer (model 394," PE Applied Biosystems, CA, USA). For generation of siRNAs, synthetic RNAs were annealed by a standard method³⁷. These siRNAs (100 nM) and synthetic miR-23 (2 μM) were then introduced into NT2 cells using Oligofectamin^TM (Invitrogen, CA, USA) according to the manufacture's protocol.

Construction of plasmids For construction of the Luc-TS23 and Luc-mTS23 expression plasmids, we used the plasmid pRL-TK (Promega, WI, USA). Five copies of the target site or of the mutant target site of miR-23 were inserted downstream of the gene for luciferase in pRL-TK. In the case of luciferase reporter genes bearing only one copy of the miR-23 target site, miR-23 barely affected translation of Luc-TS23, probably because of the strong SV40 promoter compared with the natural Hesl promoter. The nucleotide sequence of each chimeric gene was confirmed by direct sequencing.

Preparation of the nuclear fraction and the eytoplasmic fraction of ceUs

For the preparation of the eytoplasmic fraction, NT2 cells were washed twice with PBS and then resuspended in digitonin lysis buffer (50 mM HEPES/KOH, pH 7.5, 50 mM potassium acetate, 8 mM MgClz, 2 mM EGTA and δO μg/mL digitonin) on ice for 10 mins. The lysate was centrifuged at l,000x g and the supernatant was collected as the eytoplasmic fraction. The pellets were resuspended in NP-40 lysis buffer (20 mM Tris-HCl, pH 7.5, 50 mM KC1, 10 mM NaCl, 1 mM EDTA and 0.5% NP-40) and held on ice for 10 mins and the resultant lysate was used as the nuclear fraction.

Northern blotting analysis

Cytoplasmic RNA and nuclear RNA were extracted and purified from the eytoplasmic fraction and the nuclear fraction, respectively, with ISOGEN™ reagent (Wako Co., Toyama, Japan). Thirty micrograms of total RNA per lane were loaded on a polyacrylamide gel (for detection of miR-23) or agarose gel (for detection of Hesl mRNA). After electrophoresis, bands of RNA were transferred to a nylon membrane (Amersham Co., Buckinghamshire, UK). The synthetic DNA probe for Hesl and δ synthetic RNA probe for miR-23 were labeled with ³²P by T4 polynucleotide kinase (Takara Shuzo Co., Kyoto, Japan). The level of actin was measured as an endogenous control.

Amplified sandwich enzyme-linked immunosorbent assay (ELISA).

10 Amplified ELISA has been described elsewhere⁴⁵. NT2 cells, grown in the presence or absence of RA (δ μM, for 3 weeks), were harvested. Total protein was used in this assay. ELISA plates were coated with specific polyclonal antibodies against Hesl (gift from Dr. Sudo at TORAY Co.), SSEA-3 (Santa Cruz) or MAP2 (UBI, VA, USA). After the plates had been washed three times, biotinylated second antibodies,

Iδ followed by horseradish peroxidase-conjugated (HRP-eonjugated) streptavidin, were added at room temperature. Absorbance was monitored at 490 nm with a microplate reader after addition of phenylenediamine (Sigma-Aldrich Co., MO, USA).

Western blotting analysis 20 Total proteins (each 20 μg) were resolved by SDS-PAGE (10% polyacrylamide gel) and transferred to a polyvinylene difluoride (PVDF) membrane (Funakoshi Co., Tokyo, Japan) by electroblotting. Immune complexes were visualized with ECL kit (Amersham Co., Buckinghamshire, UK) using specific polyclonal antibodies against HES 1 (gift from Dr. Sudo at TORAY Co.). The relative levels of HES 1 was normalized with the level of actin.

Assay of luciferase activity. miR-23-siRNAs, synthetic miR-23 and mutant miR-23 were introduced into δ NT2 cells that expressed Luc^_TS23 or Luc-mTS23 using Oligofectamin™ (Invitrogen) according to the manufacture protocol. After incubation for 72 h, cells were harvested and lysed. Total protein was assayed for luciferase activity using a luminometer

(Lumat LB9δ01; Berthold, Bad Wildbad, Germany).

0 Immunostaining

CeUs were fixed in paraformaldehyde in PBS for 1 h. Then cells were incubated with polyclonal antibody against a SSEA-3 (Santa Cruz) or against MAP2

(UBI) for 2 h. Fluoresceinisothiocyanate-conjugated (FITC-conjugated) or rhodamine -conjugated secondary antibodies were then added. Nuclei of NT2 cells 5 were stained with 4-diamidino-2-phenyUndole (DAPI," Sigma-Aldrich Co.).

REFERENCES AU references (e.g., books, articles, applications, and patents) cited in this specification are indicative of the level of skill in the art and their disclosures are 0 incorporated herein in their entirety.

1. Eddy, S.R. Non-coding RNA genes and the modern RNA world. Nature Reviews Geneticsl, 919-929 (2001).

2. Lee, R.C., Feinbaum, R.L., & Ambros, V. The C. elegans heteroehronic gene lin-4 encodes smaU RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993). 3. Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelh, A.E., Bettinger, J.C., Rougvie, A.E., Horvitz, H.R., & Ruvkun, G. The 21-nucleotide let-7 RNA regulates developmental timing in C. elegans. Nature 403, 901-906 (2000). δ 4. Pasquinelh, A.E., Reinhart, B.J., Slack, E, Martindale, M.Q., Kuroda, M.I., Mailer, B., Hayward, D.C., BaU, E.E., Degnan, B., Muller, P., Spring, J., Srinivasan, A., Fishman, M., Finnerty, J., Corbo, J., Levine, M., Leahy, P., Davidson, E., & Ruvkun, G. Conservation of the sequence and temporal expression of 7e£-7 heterochronic regulatory RNA. Nature 408, 86-89 (2000). 0 δ. Slack, F.J., Basson, M., Liu, Z., Ambros, V., Horvitz, H.R., & Ruvkun, G. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let- 7 regulatory RNA and the LIN-29 transcription factor. Mol. Cell 5, 6δ9-669 (2000). 6. Lau, N.C., Lim, L.P., Weinstein, E.G., & Bartel, D.P. An abundant class of tiny RNAs with probable regulatory roles in C. elegans. Science, 294, 8δ8-862 (2001). 5 7. Lee, R.C., & Ambros, V. An extensive class of small RNAs in Caenorhabditis elegans. Science, 294, 862-864 (2001). 8. Lagos-Quintana, M, Rauhut, R, Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. Identification of novel genes coding for small expressed RNAs. Science 294, 853-858 (2001). 0 9. Mourelatos, Z., Dostie, J., Paushkin, S., Sharma, A., Charroux, B., Abel, L., Rappsilber, J., Mann, M., & Dreyfuss, G. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 16, 720-728 (2002). 10. Reinhart, B.J., Weinstein, E.G., Rhoades, M.W., Bartel, B., & Bartel, D.P. MicroRNAs in plants. Genes Dev. 16, 1616-1626 (2002). 11. Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12, 73δ"739 (2002). δ 12. Rhoades, M.W., Reinhart, B.J., Lim, L.P., Burge, C.B., Bartel, B., & Bartel, D.P. Prediction of plant mieroRNA targets. Cell llQ, δl3-δ20 (2002).

13. Lagos-Quintana, M., Rauhut, R., Meyer, J., Borkhardt, A., & Tuschl, T. New microRNAs from mouse and human. RNA 9, 17δ-179 (2003).

14. Lim, L.P., Glasner, M.E., Yekta, S., Burge, C.B., & Bartel, D.P. Vertebrate 0 mieroRNA genes. Science2 9, lδ40 (2003).

15. Lim, L.P., Lau, N.C., Weinstein, E.G., Abdelhakim, A., Yekta, S., Rhoades, M.W., Burge, C.B., & Bartel, D.P. The microRNAs of Caenorhabditis elegans. Genes Dev 17, 991-1008 (2003).

16. Dostie, J., Mourelatos, Z., Yang, M., Sharma, A., & Dreyfuss, G. Numerous 5 microRNPs in neuronal cells containing novel microRNAs. RNA 9, 180-186 (2003).

17. Llave, C, Xie, Z., Kasschau, K.D., & Carrington, J.C. Cleavage of Scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science 297, 2053-2056 (2002).

18. Tang, G., Reinhart, B.J., Bartel, D.P., & Zamore, P.D. A biochemical framework for 0 RNA silencing in plants. Genes Dev. 17, 49-63 (2003).

19. Olsen, PH., & Ambros, V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegansby blocking LIN- 14 protein synthesis after the initiation of translation. Dev. Biol. 216, 671-680 (1999).

20. Seggerson, K., Tang, L., & Moss, E.G. Two genetic circuits repress the Caenorhabditis elegans heterochronic gene lin-28 after translation initiation. Dev. Biol. 243, 21δ-225 (2002). 21. Lee, Y, Jeon, , Lee, J.T., Kim, S., & Kim, V.N. MieroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21, 4663-4670 (2002). 22. Grishok, A., Pasquinelh, A.E., Conte, D., Li, N., Parrish, S., Ha, I., BaiUie, D.L., Fire, A., Ruvkun, G., & Mello, C.C. Genes and mechanisms related to RNA interference regulate expression of the smaU temporal RNAs that control C. elegans developmental timing. Cell lQβ, 23-34 (2001).

23. Hutvagner, G., McLachlan, J., Pasquinelh, A.E., Balint, E., Tuschl, T., & Zamore, P.D. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7sm.a\\ temporal RNA. Science 293, 834-838 (2001).

24. Ketting, R.F., Fischer, S.E., Bernstein, E., Sijen, T, Hannon, G.J., & Plasterk, R.H. Dicer functions in RNA interference and in synthesis of smaU RNA involved in developmental timing in C. elegans. Genes Dev. lδ, 26δ4-26δ9 (2001). 25. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R., <& Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563-674 (2002).

26. Zeng, Y, Wagner, E.J., & CuUen, B.R. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human ceUs. Mol. Cell. 9, 1327-1333 (2002).

27. Zeng, Y, & CuUen, B.R. Sequence requirements for mieroRNA processing and function in human ceUs. RNA 9, 112-123 (2003).

28. Lai, E.G., and Posakony, J.W. (1997) The Bearded box, a novel 3' UTR sequence motif, mediates negative post-transcriptional regulation of Bearded and Enhancer of spht Complex gene expression Development, 124: 4847-4866. 29. Lai, E.C, Burks, C, and Posakony, J.W. (1998) The K box, a conserved 3' UTR sequence motif, negatively regulates accumulation of enhancer of spht complex transcripts. Development, 12δ: 4077-4088. 30. Lai, E.C (2002) Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nature Genet. 30: 363-364. 31. Feder, J.N., Li, L., Jan, L.Y., and Jan, Y.N. (1994) Genomic cloning and chromosomal localization of HRY, the human homolog to the Drosophila segmentation gene, hairy. Genomics, 20: 66-61. 32. Ohtsuka, T., Ishibashi, M., Gradwohl, G., Nakanishi, S., Guillemot, F., &

Kageyama, R. Hesl and Hesδ as notch effectors in mammalian neuronal differentiation. EMBO J. 18, 2196-2207 (1999). 33. Kageyama, R., Ohtsuka, T., & Tomita, K. The bHLH gene Hesl regulates differentiation of multiple cell types. Mol. Cells 29, 1-7 (2000). 34. Ohtsuka, T., Sakamoto, M., GuiUemot, F., & Kageyama, R. Roles of the basic helix-loop -helix genes Hesl and Hesδ in expansion of neural stem ceUs of the developing brain. J. Biol. Chem. 276, 30467-30474 (2001).

35. Scott, H.S., Chen, H., Rossier, C, Lalioti, M.D., and Antonarakis, S.E. (1997) Isolation of a human gene (HESl) with homology to an Escherichia coli and a zebrafish protein that maps to chromosome 21q22.3. Human Genet. 99: 616-623.

36. Cheung, W.M., Chu, P.W., Lung, C.H., & Ip, N.Y. Expression of retinoid receptors during the retinoic acid-induced neuronal differentiation of human embryonal carcinoma ceUs. J. Neurochem. 75, 34-40 (2000).

37. Elbashir, S.M., Harborth, J., Lendeckel, W, Yalcin, A., Weber, , & Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture. Nature 411, 494-498 (2001). 38. McManus, M.T. & Sharp P.A. Gene silencing in mammals by small interfering

RNAs. Nature Reviews Genetics 3, 737-747 (2002). δ 39. Fire A., Xu S., Montgomery, M.K., Kostas, S.A., Driver, S.E., & Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998). 40. Hammond, S.M., Caudy, A.A., & Hannon, G.J. Post-transcriptional gene silencing by double -stranded RNA. Nature Reviews Genetics 2, 110-119 (2001). 0 41. Pleasure, S.J., & Lee, NM. ΝTera 2 cells: a human cell line which displays characteristics expected of a human committed neuronal progenitor cell. J.

Neurosci. Res. 35, 685-602 (1993).

42. Kurie, J.M., Brown, P., Salk, E., Scheinberg, D., Birrer, M., Deutsch, P., &, Dmitrovsky, E. Cooperation between retinoic acid and phorbol esters enhances 5 human teratocarcinoma differentiation. Differentiation 54, 115-122 (1993).

43. Hutvagner, G., & Zamore, P.D. A mieroRNA in a multiple -turnover RΝAi enzyme complex. Science 297, 2056-2060 (2002).

44. Brennecke, J., Hipfner, D.R., Stark, A., Russell, R.B., & Cohen, S.M. bantam Encodes a Developmentally Regulated mieroRNA that Controls CeU Proliferation 0 and Regulates the Proapoptotic Gene hid in Drosophila. Cell 113, 25-36 (2003).

45. Kawasaki, H., Eckner, R., Yao, T. P., Taira, K., Chiu, R., Livingston, D. M., & Yokoyama, K. K. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 393, 284-289 (1998).

5 OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the foUowing claims.

TABLE 1a

TABLE 1

Claims

CLAIMSWe claim:

1. A method for modulating expression of a target gene in a cell, the method comprising introducing into the cell a polynucleotide that forms a duplex region with an mRNA transcribed from said target gene, wherein said duplex region comprises a mammalian miRNA target region.

2. The method of claim 1, wherein the miRNA target region comprises a sequence having at least about 70% identity to a polynucleotide selected from SEQ ID Nos: 5-11, 13, and 121-290.

3. The method of claim 1, wherein the polynucleotide is an miRNA or a precursor thereof, or a vector encoding said miR A or a precursor thereof.

4. The method of claim 3, wherein the miRNA comprises a sequence having at least about 70% identity to a polynucleotide selected from SEQ ID Nos: 1, 3, 12, and 14-120.

The method of claim 4, wherein the miRNA or precursor thereof is selected from the group consisting of: miR-1, miR-2-1, miR-5, miR-7, miR-8, miR- 11, miR- 12, miR-13, miR- 14, miR- 15, miR- 16, miR- 17, miR- 18, miR- 19, miR-20, miR-21, miR-22, miR-23, miR-24,miR-25, miR-26, miR-27, miR-28, miR-29, miR-30, miR-31, miR-32, miR-33, miR-34, miR-92, miR-93, miR-94, miR-95, miR-96, miR-97, miR-98, miR-99, miR-100, miRlOl, miR- 103, miR- 104, miR- 105, miR- 106 , miR- 107, miR- 109, miR- 110, miR- 111, miR- 112, miR-113,miR-114,miR-116, miR- 119, miR- 122, miR- 125, miR- 126, miR- 127, miR- 129, miR- 130, miR- 132 , miR- 133 , miR- 134 , miR- 136 , miR-13

8 ,miR-140, miR- 141, miR- 144, miR- 145, miR- 146, miR- 147, miR- 148, miR- 149, miR-150, miR-151, miR-153, miR-154, miR-157, miR-158, miR-160, miR-162, miR- 164, miR- 172, miR- 173, miR- 174, miR- 175, miR- 176, miR- 177, miR- 178, miR- 179, miR- 180, miR- 182, miR- 183, miR- 184, miR- 185, miR-186, miR- 187, miR- 188, miR- 189, miR-191, miR- 192, miR- 193, miR- 195, miR- 196, miR- 197, miR- 199, miR-201, miR-203, miR-205, and miR-224., or a precursor thereof.

6. The method of claim 4, wherein the miRNA comprises a sequence selected from the group consisting of SEQ ID Nos: 1, 3, 12, and 14-120.

7. The method of claim 1, wherein the target gene is selected from the group consisting of: dbl proto-oncogene; transforming growth factor beta l; transforming growth factor alpha; v-myb myeloblastosis viral oncogene homolog; c-cbl proto-oncogene; snol; activin beta E subunit; myogenic factor 5; fibroblast growth factor 9; RON encoding a tyrosine kinase; E3 ubiquitin Ugase

SMURFl; jagged 2; jun-B encoding the JUN-B protein; methyl-CpG binding domain protein 4; ZIP kinase; endomucin; ICE-protease activating factor; hairy and enhancer of spht 1; transforming growth factor beta 3; enaptin mRNA; AMP deaminase; interleukin 1 alpha! E2F transcription factor 6; laminin alpha; polymerase (DNA-directed) alpha; leukocyte tyrosine kinase! homeo box Dl; laminin gamma! tumor necrosis factor receptor superfamUy member 1A; vilUn 2; frizzled homolog 5; ATP-dependent chromatin remodeUing protein! MSX2 mRNA for transcription factor; adipose differentiation-related protein; myogenic factor 4; SRY (Sex determining Region Y)-box 5! Notch homolog 1!

Human tyrosine kinase-type receptor! polymerase (DNA directed) theta! cAMP responsive element binding protein 3! timeless homolog! RAD52 homolog! toll-Uke receptor 4! SRY (Sex determining Region Y) -box 9! homeo box A5! cell division cycle 42 GTP binding protein! desmushn! TFIIIC Box B-binding subunit! profUin 2; c-fms proto-oncogene; delta-like 1; fatty-acid-Coenzyme A ligase long-chain 5; discs large homolog-associated protein 2; TFIIH gene for transcription factor II H; RNA polymerase III subunit RPC; RecQ protein-Uke 5; METH2 protein; MOST2 protein; SRY (Sex determining Region Y) -box 7! integrin beta 1 subunit; desmin; protection of telomeres 1>" H2.0-Uke homeo box l; GABA transport protein; vmyc myelocytomatosis viral related oncogene neuroblastoma derived; BAG-famUy molecular chaperone regulator-5; Human placental bone morphogenic protein; retinoblastoma-associated factor 600; ALK-4; tolloid-like 2; RIGB; Human DNA repair hehcase; T-box 22; BRCAl associated protein 1! Sp3 transcription factor; TEF-1 gene; forkhead box A3; ets family transcription factor ELF2A; microtubule-associated protein 1A; myosin

5B; NEDD4-like ubiquitin ligase 1! Mintl mRNA; PARX protein," epidermal growth factor receptor! matrix metaUoproteinase 3! VE-cadherin! microtubule-associated protein 2! TAF7 RNA polymerase II TATA box binding protein (TBP)-associated factor! mitochondrial elongation factor G2! eyes absent homolog! paired box gene 3! synaptotagmin i! histone deacetylase 5! homolog of Drosophila headcase! homeo box B8! fyn-related kinase! TGF-beta/activin signal transducer FAST-lp! La autoantigen! mutL homolog 1! E74-like factor 3! B-myb gene! a-myb mRNA! jagged 1! homeobox protein SHOTb! death-associated protein kinase 3; RAD51 homolog (RecA homolog); methyl-CpG binding endonuclease; HUSl checkpoint homolog; HESl protein; caldesmon L' VENT-like homeobox 2; early growth response 2 protein; Notch3>^* lin-28 homolog! PML-3! c-myc binding protein! transducer of ERBB2 1! neuron navigator 3! multiple asters l! headcase homolog! microtubule-associated protein 6! methyl-CpG binding domain protein 1! EphA.5! polymerase (RNA) III

(DNA directed)! neuro-oncological ventral antigen 1! activating transcription factor 1! interphotoreceptor retinoid-binding protein! E2F transcription factor 3! mesoderm specific transcript homolog! bone morphogenetic protein 3! EphA3! methyl-CpG binding domain protein 5! fibroblast growth factor 12! RNA helicase A! matrix metaUoproteinase 26! crossveinless-2! cadherin 5 type

2 VE-cadherin! eukaryotic translation initiation factor 4A! TWEAK! fork head domain protein! HOXB7 gene! Paχ-3! homeobox protein SHOTa! inhibitor of growth famUy member 1! vets erythroblastosis virus E26 oncogene Uke! reticulon 4! NOD2 protein! interleukin 6 receptor! PML-2 mRNA! discs large homolog 1! Yes-associated protein l! CD 14 antigen! negative differentiation regulator! CREB binding protein! vski sarcoma viral oncogene homolog! sidekick homolog 1! bone morphogenetic protein receptor type II; programmed cell death 10,^* cycUn H! nuclear protein double minute 1! BCL2/adenovirus EIB 19kDa interacting protein 2! karyopherin beta 2! and vros UR2 sarcoma virus oncogene homolog 1.

8. The method of claim 7, wherein the mRNA transcribed from said target gene comprises a polynucleotide sequence having at least 70% identity to a polynucleotide selected from SEQ ID Nos: Nos: 5-11, 13, and 121-290.

9. The method of claim 7, wherein said target gene comprises a polynucleotide sequence that hybridizes under moderately stringent conditions with a polynucleotide sequence selected from SEQ ID Nos: 291-454.

10. A method for modulating expression of a mammaUan target gene in a cell, the method comprising introducing into the ceU an siRNA that forms a duplex region with an miRNA, or precursor thereof, wherein an mRNA transcribed from said target gene comprises an miRNA target region.

11. The method of claim 10, wherein the siRNA forms a duplex region with an miRNA, thereby inhibiting the miRNA from forming a second duplex region with mRNA transcribed from said target gene.

12. The method of claim 10, wherein the siRNA forms a duplex region with an miRNA precursor, thereby inhibiting the miRNA precursor from converting to miRNA.

13. The method of claim 10, wherein the miRNA target region comprises a sequence having at least about 70% identity to a polynucleotide selected from SEQ ID Nos: 5-11, 13, and 121-290.

14. The method of claim 10, wherein the miRNA or precursor thereof comprises a sequence having at least about 70% identity to a polynucleotide selected from

SEQ ID Nos: l, 3, 12, and 14-120.

15. The method of claim 14, wherein the miRNA or precursor thereof is selected from the group consisting of: miR-1, miR-2-1, miR-5, miR-7, miR-8, miR- 11, miR- 12, miR-13, miR- 14, miR- 15, miR- 16, miR- 17, miR- 18, miR- 19, miR-20, miR-21, miR-22, miR-23, miR-24,miR-25, miR-26, miR-27, miR-28, miR-29, mi.R-30, miR-31, miR-32, miR-33, miR-34, miR-92, miR-93, miR-94, miR-95, miR-96, miR-97, miR-98, miR-99, miR-100, miRlOl, miR-103, miR- 104, miR- 105, miR- 106 , miR- 107, miR- 109, miR- 110, miR- 111, miR- 112, miR-113,miR-114,miR-116, miR- 119, miR- 122, miR- 125, miR- 126, miR- 127, miR-129, miR-130, miR-132 , miR-133 , miR-134 , miR- 136 , miR-13 8 ,miR-140, miR- 141, miR- 144, miR- 145, miR- 146, miR- 147, miR- 148, miR- 149, miR- 150, miR- 151, miR- 153, miR- 154, miR- 157, miR- 158, miR- 160, miR- 162, miR- 164, miR- 172, miR- 173, miR- 174, miR- 175, miR- 176, miR- 177, miR- 178, miR- 179, miR- 180, miR- 182, miR- 183, miR- 184, miR- 185, miR-186, miR- 187, miR- 188, miR- 189, miR-191, miR- 192, miR- 193, miR- 195, miR- 196, miR- 197, miR- 199, miR-201, miR-203, miR-205, and miR-224., or a precursor thereof.

16. The method of claim 14, wherein the miRNA or precursor thereof comprises a sequence selected from the group consisting of SEQ ID Nos: 1, 3, 12, and 14-120.

17. The method of claim 10, wherein the target gene is selected from the group consisting of: dbl proto-oncogene; transforming growth factor beta 1! transforming growth factor alpha; vmyb myeloblastosis viral oncogene homolog! c-cbl proto-oncogene! snol! activin beta E subunit! myogenic factor 5! fibroblast growth factor 9! RON encoding a tyrosine kinase! E3 ubiquitin Ugase SMURFl! jagged 2,' jun-B encoding the JUN-B protein; methyl-CpG binding domain protein 4,^' ZIP kinase; endomucin! ICE-protease activating factor; hairy and enhancer of spht 1,' transforming growth factor beta 3; enaptin mRNA; AMP deaminase; interleukin 1 alpha; E2F transcription factor 6; laminin alpha; polymerase (DNA-directed) alpha,' leukocyte tyrosine kinase; homeo box Dl! laminin gamma! tumor necrosis factor receptor superfamily member 1A,' villin 2! frizzled homolog 5! ATP-dependent chromatin remodelling protein!

MSX2 mRNA for transcription factor! adipose differentiation-related protein! myogenic factor 4! SRY (Sex determining Region Y) -box 5! Notch homolog 1! Human tyrosine kinase-type receptor! polymerase (DNA directed) theta! cAMP responsive element binding protein 3! timeless homolog! RAD52 homolog! toll-Uke receptor 4! SRY (Sex determining Region Y)"box 9! homeo bo Aδ; ceU division cycle 42 GTP binding protein," desmusUn," TFIIIC Box B-binding subunit; profihn 2; c-fms proto-oncogene; delta-like 1; fattyacid-Coenzyme A Ugase long-chain 5; discs large homolog-associated protein 2; TFIIH gene for transcription factor II H,^" RNA polymerase III subunit RPC^* RecQ protein-Uke 5; METH2 protein; MOST2 protein,^" SRY (Sex determining Region Y)-box T, integrin beta 1 subunit; desmin; protection of telomeres 1," H2.0"Uke homeo box l; GABA transport protein," v-myc myelocytomatosis viral related oncogene neuroblastoma derived,' BAG-family molecular chaperone regulator-5; Human placental bone morphogenic protein; retinoblastoma-associated factor 600,"

ALK-4; tolloid-like 2,^* RIGB; Human DNA repair hehcase,^* T-box 22,^* BRCAl associated protein 1>" Sp3 transcription factor; TEF-1 gene; forkhead box A3; ets family transcription factor ELF2A; microtubule-associated protein 1A; myosin 5B; NEDD4-like ubiquitin ligase l; Mintl mRNA," PARX protein," epidermal growth factor receptor," matrix metaUoproteinase 3; VE-cadherin; microtubule-associated protein 2; TAF7 RNA polymerase II TATA box binding protein (TBP) -associated factor; mitochondrial elongation factor G2; eyes absent homolog," paired box gene 3; synaptotagmin I," histone deacetylase 5," homolog of DrosophUa headcase; homeo box B8," fyn-related kinase; TGF-beta/activin signal transducer FAST-lp; La autoantigen," mutL homolog 1!

E74-like factor 3,^" B-myb gene,^* a-myb mRNA,^* jagged 1,^* homeobox protein SHOTb,^* death-associated protein kinase 3,' RAD51 homolog (RecA homolog); methyl-CpG binding endonuclease,' HUSl checkpoint homolog; HESl protein,' caldesmon 1! VENT-like homeobox 2," early growth response 2 protein,' Notch3; lin-28 homolog," PML-3; c-myc binding protein,' transducer of ERBB2 l; neuron navigator 3; multiple asters 1) headcase homolog," microtubule-associated protein 6; methyl-CpG binding domain protein 1! EphA5," polymerase (RNA) III (DNA directed),' neuro-oncological ventral antigen 1," activating transcription factor 1," interphotoreceptor retinoid-binding protein; E2F transcription factor 3! mesoderm specific transcript homolog! bone morphogenetic protein 3! EphA3! methyl-CpG binding domain protein 5! fibroblast growth factor 12! RNA helicase A," matrix metaUoproteinase 26," crossveinless-2! cadherin 5 type 2 VE-cadherin! eukaryotic translation initiation factor 4A! TWEAK,' fork head domain protein! HOXB7 gene! Paχ-3! homeobox protein SHOTa! inhibitor of growth famUy member 1! vets erythroblastosis virus E26 oncogene like! reticulon 4! NOD2 protein! interleukin 6 receptor! PML-2 mRNA; discs large homolog I,' Yes-associated protein 1," CD 14 antigen,' negative differentiation regulator! CREB binding protein,' vski sarcoma viral oncogene homolog; sidekick homolog l! bone morphogenetic protein receptor type IL' programmed cell death 10! cycUn H," nuclear protein double minute 1! BCL2/adenovirus EIB 19kDa interacting protein 2! karyopherin beta 2! and v-ros UR2 sarcoma virus oncogene homolog 1.

18. The method of claim 17, wherein the mRNA transcribed from said target gene comprises a polynucleotide sequence having at least about 70% identity to a polynucleotide selected from SEQ ID Nos: l_; 3_; 12, and 14-120.

19. The method of claim 17, wherein said target gene comprises a polynucleotide sequence that hybridizes under moderately stringent conditions with a polynucleotide sequence selected from SEQ ID Nos: 291-454.

20. The method of claim 1 or 10, further comprising measuring expression of said target gene.

21. The method of claim 1 or 10, wherein the method modulates ontogenesis, function, differentiation and/or viabUity of a mammalian cell.

22. A method for controlUng ontogenesis of mammal, function of mammaUan cell, differentiation of mammalian ceU or viabihty of mammalian ceU in the post-transcriptional phase, the method comprising introducing into the cell a miRNA or a siRNA silencing precursor to the the miRNA.

23. The method defined in claim 10 or 22, wherein the siRNA binds to a loop in stem-loop structure of the miRNA or precursor thereof.

24. The method of any claim of 10 to 23, wherein the siRNA targets miRNA and has a sequence with at least about 70% identity to the sequence disclosed in SEQ ID No: 2.

25. The method of any claim of 10 to 24, wherein the method controls differentiation of nerve cell by regulating expression of hairy and enhancer of split 1.

26. A plasmid vector comprising a promoter and a polynucleotide sequence expressing miRNA or a precursor to the miRNA.

27. A plasmid vector comprising from a promoter and a nucleotide sequence expressing siRNA silencing precursor to miRNA.

28. The plasmid vector of claim 26 or 27, wherein the miRNA is capable of forming a duplex region with an mRNA transcribed from a mammalian target gene.

29. The plasmid vector defined in claim 27 or 28, wherein the promoter is tRNA^^val) promoter.

30. The plasmid vector defined in claim 27 or 28, wherein the promoter is selected from the group consisting of tRNA^(val) promoter, U6 promoter, HI promoter and

Pol II promoter, such as CMV and SV40 promoter.

31. A method for controlling ontogenesis of mammal, function of mammaUan cell, differentiation of mammalian ceU or viabUity of mammalian ceU in the post-transcriptional phase introducing into the cell the plasmid vector defined in any of claims 27 to 28.

32. A method for treating cancer, immune disease, nerve disorder or inflammatory disease, the method comprising introducing into a cell an miRNA, a siRNA silencing precursor to the miRNA or the plasmid vector defined in any of claims

27 to 28.

33. The method defined in claim 32, wherein the nerve disorder is selected from amyotrophic lateral sclerosis (ALS), Parkinson disease or Alzheimer disease.

34. A method for screening pharmaceuticals using a miRNA, a siRNA sUencing precursor to the miRNA or the plasmid vector defined defined in any of claims 27 to 28.

35. The method defined in claim 34, wherein the target mRNA is derived from a recombinant gene having a sequence of the target region of the miRNA.

36. A method for gene function analysis using a miRNA, a siRNA silencing precursor to the miRNA or the plasmid vector defined in any of claims 27 to 28.

37. A method for regulation of cell differentiation to muscle ceU, bone cell or myocardial cell, identified by the gene function analysis defined in claim 36.

38. A method for preservation or maintenance of anaplastic cell, introducing into cell a substance suppressing expression of miR-23.

39. A method for regulating ratio of gene expression, by producing recombinant of selected gene and target sequence of miR-23 of Hesl, and designing miR-23 sequence 50 to 90% complementary to the target sequence.

40. A method for suppressing gene expression, introducing into cell a siRNA inducing decomposition of mRNA and a miRNA.

1. The method defined in claim 40, wherein the miRNA is miR-23.